NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY
Chronic Myeloid Leukemia, Version 2.2024
NeilP. Shah,MD, PhD1,*;Ravi Bhatia, MD2,*; JessicaK.Altman,MD3; MariaAmaya, MD,PhD4; KebedeH.Begna, MD5;
Ellin Berman,MD6; OnyeeChan,MD7; JoanClements8; RobertH.CollinsJr, MD9;Peter T. Curtin, MD10;
DanielJ.DeAngelo, MD,PhD11;Michael Drazer, MD12; LoriManess,MD13;Leland Metheny,MD14;
SanjayMohan,MD, MSCI15; Joseph O.Moore, MD16; VivianOehler,MD17;KeithPratz,MD18;
IskraPusic, MD,MSCI19;Michal G.Rose, MD20; William Shomali, MD21; B.DouglasSmith, MD22; MichaelStyler,MD23;
MosheTalpaz,MD24;Tiffany N.Tanaka,MD25;SrinivasTantravahi, MBBS26; JamesThompson,MD, MS27;
StevenTsai,MD28;JenniferVaughn,MD, MSPH29;JeannaWelborn,MD30;DavidT. Yang, MD31;
Hema Sundar,PhD32; andKristinaGregory, RN,MSN32
ABSTRACT
NCCNCATEGORIESOFEVIDENCEANDCONSENSUS
Category1:Baseduponhigh-levelevidence,thereisuniform
Chronic myeloid leukemia (CML) is defined by the presence of NCCNconsensusthattheinterventionisappropriate.
Philadelphiachromosomeresultingfromareciprocaltranslocationbe- Category2A:Baseduponlower-levelevidence,thereisuniform
tweenchromosomes9and22[t9;22]thatgivesrisetoaBCR::ABL1fu- NCCNconsensusthattheinterventionisappropriate.
siongene.CMLoccursin3differentphases(chronic,accelerated,and Category 2B: Based upon lower-level evidence, there is
blastphase)andisusuallydiagnosedinthechronicphaseindevel- NCCNconsensusthattheinterventionisappropriate.
opedcountries.Tyrosinekinaseinhibitor(TKI)therapyisahighlyeffec-
Category3:Baseduponanylevelofevidence,thereismajor
tivetreatmentoptionforpatientswithchronicphase–CML.Theprimary
NCCNdisagreementthattheinterventionisappropriate.
goalofTKItherapyinpatientswithchronicphase–CMListoprevent
diseaseprogressiontoacceleratedphase–CMLorblastphase–CML. Allrecommendationsarecategory2Aunlessotherwisenoted.
DiscontinuationofTKItherapywithcarefulmonitoringisfeasibleinse-
lectedpatients.Thismanuscriptdiscussestherecommendationsout- Clinicaltrials:NCCNbelievesthatthebestmanagementof
linedintheNCCNGuidelinesforthediagnosisandmanagementof anypatientwithcancerisinaclinicaltrial.Participationin
patientswithchronicphase–CML. clinicaltrialsisespeciallyencouraged.
JNatlComprCancNetw2024;22(1):43–69
doi:10.6004/jnccn.2024.0007 PLEASENOTE
The NCCN Clinical Practice Guidelines in Oncology (NCCN
Guidelines®)areastatementofevidenceandconsensusofthe
authorsregardingtheirviewsofcurrentlyacceptedapproaches
totreatment.AnyclinicianseekingtoapplyorconsulttheNCCN
Guidelinesisexpectedtouseindependentmedicaljudgmentin
thecontextofindividualclinicalcircumstancestodetermineany
patient’scareortreatment.TheNationalComprehensiveCancer
Network®(NCCN®)makesnorepresentationsorwarrantiesof
1UCSFHelenDillerFamilyComprehensiveCancerCenter;2O’Neal anykindregardingtheircontent,use,orapplicationanddisclaims
ComprehensiveCancerCenteratUAB;3RobertH.LurieComprehensiveCancer anyresponsibilityfortheirapplicationoruseinanyway.
CenterofNorthwesternUniversity;4UniversityofColoradoCancerCenter;
5MayoClinicComprehensiveCancerCenter;6MemorialSloanKetteringCancer ThecompleteNCCNGuidelinesforChronicMyeloidLeuke-
Center;7MoffittCancerCenter;8CMLBusterFoundation;9UTSouthwestern miaare notprinted inthisissue of JNCCN but can be ac-
SimmonsComprehensiveCancerCenter;10CityofHopeNationalMedical cessedonlineatNCCN.org.
Center;11Dana-Farber/BrighamandWomen’sCancerCenter;12TheUChicago
©2024,NationalComprehensiveCancerNetwork®(NCCN®).
MedicineComprehensiveCancerCenter;13FredandPamelaBuffettCancer
Allrightsreserved.TheNCCNGuidelinesandtheillustrations
Center;14CaseComprehensiveCancerCenterUniversityHospitalsSeidman
hereinmaynotbereproducedinanyformwithouttheexpress
CancerCenterandClevelandClinicTaussigCancerInstitute;15Vanderbilt-
writtenpermissionofNCCN.
IngramCancerCenter;16DukeCancerInstitute;17FredHutchinsonCancer
Center;18AbramsonCancerCenterattheUniversityofPennsylvania;19Siteman
DisclosuresfortheNCCNChronicMyeloidLeukemia
CancerCenteratBarnes-JewishHospitalandWashingtonUniversitySchoolof
Panel
Medicine;20YaleCancerCenter/SmilowCancerHospital;21StanfordCancer
Institute;22TheSidneyKimmelComprehensiveCancerCenteratJohnsHopkins; AtthebeginningofeachNCCNGuidelinesPanelmeeting,panel
23FoxChaseCancerCenter;24UniversityofMichiganRogelCancerCenter; membersreviewallpotentialconflictsofinterest.NCCN,in
25UCSanDiegoMooresCancerCenter;26HuntsmanCancerInstituteatthe keepingwithitscommitmenttopublictransparency,publishes
UniversityofUtah;27RoswellParkComprehensiveCancerCenter; thesedisclosuresforpanelmembers,staff,andNCCNitself.
28UCLAJonssonComprehensiveCancerCenter;29TheOhioStateUniversity
IndividualdisclosuresfortheNCCNChronicMyeloidLeukemia
ComprehensiveCancerCenter-JamesCancerHospitalandSoloveResearch
Panelmemberscanbefoundonpage69.(Themostrecentver-
Institute;30UCDavisComprehensiveCancerCenter;31UniversityofWisconsin
sionoftheseguidelinesandaccompanyingdisclosuresareavail-
CarboneCancerCenter;and32NationalComprehensiveCancerNetwork.
ableatNCCN.org.)
*DiscussionWritingCommitteeMember. Thecompleteandmostrecentversionoftheseguidelinesis
availablefreeofchargeatNCCN.org.
Supplementarymaterialispublishedonlineathttps://doi.org/10.6004/jnccn.2024.0007
JNCCN.org | Volume22 Issue1 | February2024 43

NCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024
Overview usually produced in the setting of Ph-positive acute lym-
Chronicmyeloidleukemia(CML)accountsfor15%ofadult phoblasticleukemia,andp230isassociatedwithenhanced
leukemias. The median age of disease onset is 67 years; neutrophil differentiation. Atypical BCR::ABL1 transcripts
however,CMLoccursinallagegroups(SEERstatistics). (eg, e13a3, e14a3, e6a2) have also been detected in about
In 2023, an estimated 8,930 people will be diagnosed 1%–2% of patients with CML. The proportion of different
withCMLintheUnitedStates,and1,310peoplewilldie BCR::ABL1 transcripts and the impact of BCR::ABL1 tran-
ofthedisease.1 script type on response to tyrosine kinase inhibitor (TKI)
CML is defined by the presence of the Philadelphia therapyarediscussedinthesection“BCR::ABL1Transcript
chromosome (Ph) in a patient with a myeloproliferative VariantsinCML”(page46).
neoplasm.Phresultsfromareciprocaltranslocationbe- CMLoccursin3differentphases(chronic,accelerated,
tweenchromosomes 9 and 22 [t9;22] that gives rise to a and blast phase) and is usually diagnosed in the chronic
BCR::ABL1 fusion gene.2 In most patients, the chromo- phase in developed countries. Untreated chronic phase
somal breakpoints are located in intron 13 or 14 of the CML (CP-CML) will eventually progress to accelerated
BCR gene on chromosome 22 (major breakpoint cluster phase CML (AP-CML) or blast phase CML (BP-CML) in 3
region; M-BCR). In the ABL1 gene they are located be- to 5 years on average.5 Progression to AP-CML and BP-
tweenthe2alternativeABL1exonsIbandIa,orbetween CMLbridgesacontinuumofclinicalfeatures(ie,fever,bone
ABL1 exons 1 and 2.3,4 Irrespective of the precise ABL1 pain, spleen size), cytogenetic changes, and blast count.
breakpoint,splicingalmostinvariablyfusesABL1exon2 Gene expressionprofilinghasshowna close correlationof
with BCR exons 13 or 14, resulting in e13a2 and e14a2 gene expression between AP-CML and BP-CML indicating
transcriptsthatcodeforaprotein,p210,withderegulated thatthebulkofthegeneticchangesinprogressionoccur
tyrosinekinaseactivity,whichcausesCML. inthetransitionfromCP-CMLtoAP-CML.6Theactivation
UnusualBCR::ABL1transcripts,e1a2encodingforp190 ofthebeta-cateninsignalingpathwayinCMLgranulocyte-
(involvingtheminorbreakpointclusterregion;m-BCR),or macrophageprogenitors(whichenhancestheself-renewal
e19a2 encoding for p230 (involving the micro breakpoint activityandleukemicpotentialofthesecells)maybeakey
cluster region; m-BCR), are found infrequently.3,4 p190 is pathobiologiceventintheevolutiontoBP-CML.7
44 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024

ChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®
The NCCN Clinical Practice Guidelines in Oncology genescanbeusedtoconfirmthediagnosisofCML.Inter-
(NCCNGuidelines)forCMLdiscusstheclinicalmanage- phase FISH is performed on peripheral blood but can be
mentofCMLinall3phases(chronic,accelerated,orblast associated with a false-positive rate of 1%–5% depending
phase).EvaluationfordiseasesotherthanCMLasoutlined onthespecificprobeusedintheassay.13Hypermetaphase
intheNCCNGuidelinesforMyeloproliferativeNeoplasms FISH is more sensitive and can analyze up to 500 meta-
is recommended for all patients with BCR::ABL1-negative phasesatatime,butitisapplicableonlytodividingcells
myeloproliferativeneoplasm. in the bone marrow.14 Double-fusion FISH is associated
with low false-positive rates and can detect all variant
Diagnosis and Workup translocationsofthePh-chromosome.15
Initialevaluationshouldconsistofahistoryandphysical Quantitative RT-PCR (qPCR) should be done at ini-
examination,includingpalpationofthespleen,complete tial workup to establish the presence of quantifiable
bloodcountwithdifferential,chemistryprofile,andhepa- BCR::ABL1mRNAtranscripts.qPCR,usuallydoneonpe-
titis B panel. Bone marrow aspirate and biopsy for mor- ripheral blood, is the most sensitive assay available for
phologic and cytogenetic evaluation and quantitative the measurement of BCR::ABL1 mRNA and it can detect
reverse transcriptionpolymerase chainreaction(RT-PCR) oneCMLcellinabackgroundof$100,000normalcells.
toestablishthepresenceofquantifiableBCR::ABL1mRNA qPCR results can be expressed in various ways, such as
transcripts at baseline are recommended to confirm the theratioofBCR::ABL1transcriptnumberstothenumber
diagnosisofCML(SeepageCML-1). of control gene transcripts.16 An International Scale (IS)
Bone marrow cytogenetics with a minimum of 20 has been established to standardize molecular monitor-
metaphases is useful to detect additional chromosomal ing with qPCR across different laboratories with the use
abnormalities (ACAs) in Ph-positive cells, also known as of1of3controlgenes(BCR,ABL1,orGUSB)andaqPCR
clonalcytogeneticevolution(discussedinnextsection).8–12
assaywithasensitivityofatleast4-logreductionfromthe
Ifbonemarrowevaluationisnotfeasible,fluorescencein standardizedbaseline.17IShasbecomethegoldstandard
situhybridization(FISH)onthebonemarroworaperiph- of expressing qPCR values. More details on monitoring
eral blood specimen with dual probes for BCR and ABL1 with qPCR using the IS are provided in a later section.
JNCCN.org | Volume22 Issue1 | February2024 45

NCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024
QualitativeRT-PCRfordetectingatypicalBCR::ABL1tran- shown a trend toward better survival outcomes with
scripts should be considered if there is discordance be- e14a2 transcript,24,25 in other studies the type of tran-
tween FISH and qPCR results. See the section on script did not have any significant impact on long-term
“BCR::ABL1TranscriptVariantsinCML”(nextsection). survivaloutcomes.23,26,29
BCR::ABL1transcriptsintheperipheralbloodatvery Limited available data from studies that evaluated
low levels (1–10 of 108 peripheral blood leukocytes) can the impact of BCR::ABL1 transcript variants on response
bedetectedinapproximately30%ofindividualswithout tosecond-generation(2G)TKItherapysuggestthatnilo-
CML, and the incidence of this increases with age. The tinibmaybeassociatedwithinferiormolecularresponse
riskofdevelopingCMLfortheseindividualsisextremely rates in patients with e13a2 as well as e14a2 transcripts
low, and neither continued monitoring nor therapy is comparedwithimatinib800mgordasatinib.24,30There-
indicated.18,19 sults of another studyindicate that the difference in the
amplification characteristics between the e13a2 and
BCR::ABL1TranscriptVariantsinCML e14a2transcriptscanaffectthemeasurementofresidual
e13a2 and e14a2 transcripts (both encoding for p210) disease, thus emphasizing the need to consider sequen-
were the most common BCR::ABL1 transcript variants tialmeasurementofminimalresidualdiseaseinaddition
identifiedinabout39%and62%ofpatients,respectively; to the achievement of response milestones at specific
e13a2 was more frequent in males and the proportion timepoints.31
decreasedwithageinbothsexes.20,21Unusualoratypical The presence of e1a2 transcript (encoding for p190)
transcripts were identified in about 2% of patients, with isassociatedwithahigherriskofdiseaseprogression,in-
e1a2,e19a2,e13a3,ande14a3beingthemostfrequently ferior cytogenetic and molecular responses to TKI ther-
identified transcripts.20 The incidence of these atypical apy,andthepresenceoffrequentmutationsinepigenetic
transcriptswashigherinfemalesandtheproportionde- modifiers genes.32–38 In a multivariate analysis, the e1a2
creasedwithageinbothgenders.Thepresenceofe14a2 transcriptwasalsoidentifiedasanindependentpredictor
at baseline was associated with higher molecular re- ofinferiorsurvivaloutcomes.34Itisimportanttobeaware
sponseratestoimatinib.22–28Althoughsomestudieshave
that these data refer to the presence of dominant e1a2
46 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024

ChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®
transcript,nottothepresenceoflow-levele1a2transcripts of“majorroute”ACAsinPh-positivecells(trisomy8,iso-
inpatientswithdominante13a2ore14a2transcripts.The chromosome 17q, second Ph, trisomy 19, and chromo-
presenceofe19a2transcript(encodingforp230)isasso- some 3 abnormalities) at diagnosis may have a negative
ciated with lower rates of cytogenetic and molecular prognosticimpactonsurvivalanddiseaseprogressionto
responsetoTKIsandinferiorsurvivaloutcomes,despite
acceleratedorblastphase.49–52However,inanotheranal-
previous reports of an indolent disease course in the ysis that evaluated the outcomes of patients with CP-
pre-TKI era.35,36,39 Referral to centers with expertise in CML(withorwithout ACAs)treated withTKItherapyin
themanagementofCMLisrecommended. prospective studies, the presence of ACAs in Ph-positive
Qualitative RT-PCR, nested RT-PCR, or Sanger se- cells at the time of diagnosis was not associated with
quencing are useful for identifying atypical BCR::ABL1 worse prognosis.53 Survival outcomes were not signifi-
transcripts.40,41qPCRusinglog-reductionfromstandard- cantlydifferentamongpatientswithACAsinPh-positive
ized baseline can be used to monitor e1a2 transcripts, cellsbasedonTKItherapy(imatinibvs2GTKIs)orimati-
and monitoring e19a2 transcripts is usually performed nibdose(400vs800mg).Itremainsuncertainif2GTKIs
using qualitative RT-PCR or nested RT-PCR. However, or high-dose imatinib would be more beneficial for pa-
there are no standardized qPCR assays for monitoring tients with ACAs in Ph-positive cells. Patients with ACAs
molecularresponsetoTKItherapyinpatientswithatypi- in Ph-positive cells at diagnosis should be monitored
cal BCR::ABL1 transcripts.42,43 The utility of multiplex carefully for evidence of resistance to TKI therapy, and
PCR assays and patient-specific genomic DNA quantita- follow-up metaphase karyotype analysis should be per-
tive PCR assays for monitoring atypical BCR::ABL1 tran- formedifresistanceisevident.
scriptshasbeendemonstratedinsomereports.44–48 ClonalcytogeneticevolutioninPh-negativecellshas
also been reported in a small subset of patients treated
ClonalCytogeneticEvolution with TKI
therapy.54–65
The most common abnormalities
The prognostic significance of ACAs in Ph-positive cells includetrisomy8andlossoftheYchromosome.Previous
is related to the specific chromosomal abnormality and work suggested that the overall prognosis of Ph-negative
otherfeaturesoftheacceleratedphase.8–12Thepresence
clonal evolution is good and depends on response to
JNCCN.org | Volume22 Issue1 | February2024 47

NCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024
imatinib therapy.58 However, the presence of chromo- clinicaltrials.Higherage,higherperipheralblasts,bigger
someabnormalitiesotherthanlossoftheYchromosome spleen,andlowplateletcountsweresignificantlyassoci-
has been associated with decreased survival in patients ated with increased probabilities of dying of CML. Pa-
with CP-CML treated with various TKIs, suggesting that tients in the intermediate-and the high-risk groups had
closer follow-up is indicated.66 Progression to myelodys- significantly higher probabilities of dying of CML than
plastic syndromes and acute myeloid leukemia have those in the low-risk group, and the probabilities were
beenreportedinpatientswithmonosomy7(del7q).67–69 alsosignificantlydifferentbetweentheintermediate-and
high-riskgroups.Unlikeotherscoringsystems,theELTS
score is focused on CML-specific overall survival (OS).
AdditionalEvaluation
This is important, because many patients with CML die
CP-CML:RiskStratification
ofnon-CMLcauses,reflectingtheefficacyofTKItherapy.
Sokaland Hasford (Euro)scoringsystemshave beenused Determination of risk score using either the Sokal or
fortheriskstratificationofpatientsinto3riskgroups(low, EuroorELTSscoringsystemsbeforestartofTKItherapyis
intermediate,andhigh)inclinicaltrialsevaluatingTKIs.70,71
recommendedforpatientsdiagnosedwithCP-CML.70–72
TheSokalscoreisbasedonthepatient’sage,spleensizeon
clinical examination, platelet count, and percentage of MyeloidMutationalAnalysis
blastsintheperipheralblood.70TheEuroscoreincludeseo- Mutations in epigenetic modifier genes (eg, ASXL1,
sinophilsandbasophilsintheperipheralbloodinaddition IKZF1, BCOR, TET1/2, IDH1/2, DNMT3A/3B, EZH2) have
tothesameclinicalvariablesusedintheSokalscore.71 been described in patients with CML, and the presence
The European Treatment and Outcome Study long- of epigenetic gene mutations at diagnosis has also been
termsurvival(ELTS)scoreisbasedonthesamevariables associated with lower rates of molecular/cytogenetic re-
astheSokolscoreandprovidesthemostusefulpredictor sponses and lower rates of progression-free survival
of CML-related death in patients treated with first-line (PFS)/event-freesurvival(EFS).73–87
imatinib.72TheELTSscorehasbeenvalidatedinacohort Mutations in the ASXL1 gene are the most com-
of1,120patientswithCP-CMLtreatedwithimatinibin6 monly described secondary alterations in patients with
48 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024

ChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®
CP-CML and are an independent predictor of inferior Next-generation sequencing (NGS) allows for the
molecular/cytogeneticresponsesandEFSratesafterTKI detectionoflow-levelBCR::ABL1kinasedomainmuta-
therapy(including 2G-TKI therapy).86,87 Inan analysis of tions and mutations in genes other than BCR::ABL1
222 patients with CP-CML (prospectively enrolled inthe that may confer resistance to TKIs or portend disease
CML-V study), an ASXL1 mutation was detected in 20 progression.89,90 In a prospective, multicenter study
patients at the time of diagnosis. All patients had re- (NEXT-in-CML) that assessed the feasibility of NGS to
ceived nilotinib-based TKI therapy. The probability of detectlow-levelmutationsin236consecutivepatients
experiencingmajormolecularresponse(MMR)orbetter withCMLand aninadequateresponse toTKItherapy,
at12monthswassignificantlylowerforpatientswithan NGS was more effective than conventional Sanger se-
ASXL1mutation(55%;P5.0036)comparedwith85%for quencing in the detection of low-level mutations.90
patients with no mutations and 82% for patients with Prospective monitoring of mutation kinetics demon-
othernon-ASXL1mutations.87However,inanotherstudy stratedthatTKI-resistantlow-levelmutationsareinvari-
of124patientswithnewlydiagnosedCP-CML,mutations ablyselectedifthe patients are notswitchedtoanother
inepigeneticmodifiergenes(includingASXL1mutation) TKI or if they are switched to an inappropriate TKI or
werepredictiveofresponseratesonlyinpatientstreated TKIdose.90NGSwithmyeloidmutationpanelshouldbe
with imatinib but did not have any impact on the out- considered for patients with no identifiable BCR::ABL1
comesinpatientstreatedwith2GTKIs.81 mutations.
IKZF1exondeletionsandmutationsinASXL1,RUNX1, TestingforBCR::ABL1–independentmutationsusing
and BCOR genes were the most frequently described NGSwithmyeloidmutationpanelmaybeusefulforpa-
secondary alterations in advanced phase–CML, while tients with CP-CML who do not experience optimal re-
IDH1/2 mutations were detected at a markedly lower sponsemilestonesduetothepresenceofcytopenias,for
frequency.74,79,82,84,85IKZF1,RUNX1,andDNMT3Aalter- thosepatientswithTKI-resistantdiseaseandforpatients
ations were identified as important markers of disease with advanced phase–CML.80,83 However, there are very
progressiontoadvancedphase–CMLandriskofrelapse limited data on the impact of BCR::ABL1–independent
afterdiscontinuationofTKI.73,75,79,88 mutations in patients with newly diagnosed CP-CML.
JNCCN.org | Volume22 Issue1 | February2024 49

NCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024
Additionally,BCR::ABL1–independentgenemutationshave Theselectionoffirst-lineTKItherapy(bosutinib,da-
alsobeenfrequentlydescribedinPh-negativeclones.91The satinib, imatinib, or nilotinib) in a given patient should
impactofmutationsisalsovariabledependingonwhether be based on the riskscore, toxicity profile,patient’s age,
theyoccurinPh-positiveorPh-negativeclones. abilitytotoleratetherapy,andthepresenceofcomorbid
MyeloidmutationalanalysisusingNGScanbeconsid- conditions (see page CML-2). Allogeneic hematopoietic
eredforpatientswithCP-CMLandadvancedphase–CML celltransplantation(HCT)isnolongerrecommendedas
atdiagnosis.Thisisacategory2Brecommendationforpa- afirst-linetreatmentofpatientswithCP-CML.
tientswithnewlydiagnosedCP-CML.
ClinicalConsiderationsfortheSelectionof
Management of CP-CML First-LineTherapy
PrimaryTreatment RiskStratification
Long-termefficacydatafromrandomizedphaseIIIstudies Imatinib (400 mg daily) and 2G TKIs (bosutinib [400 mg
forfirst-lineTKItherapyinpatientswithnewlydiagnosed daily],dasatinib[100mgoncedaily],andnilotinib[300mg
CP-CML are summarized in Table S1 in the Supplemen- twice daily]) are all appropriate options for first-line
tary material (available online with this
article).92–96
In TKI therapy for patients with CP-CML across all risk
summary,(1)allTKIsrecommendedarehighlyeffectivein
scores.92–96
newlydiagnosedCP-CML,withlong-termOSexpectedto Thegenericversionofinnovatordrug(imatinib)has
be similar to that of aged-matched controls; (2) 2G TKIs, beenshowntobenoninferiortoinnovatordrug(imatinib)
compared with imatinib, generally result in faster cytoge-
intermsofefficacywithanacceptabletoxicityprofile.97–99
neticandmolecularresponses,withlessprogressiontoad- A US FDA-approved generic version is an appropriate
vanced phase–CML; and (3) as of yet, in randomized substitute for an innovator drug (imatinib).100 Innova-
clinicaltrials,there are no significant differences inOSin tor and generic drugs approved by the regulatory au-
patientswhostartimatinibversusa2GTKI(dasatinib, thorities based on pharmacokinetic equivalence can
nilotinib,andbosutinib). beusedinterchangeably.
50 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024

ChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®
Data from randomized phase III studies that have (see Supplementary Table S3), which may facilitate
evaluated high-dose imatinib as first-line therapy for CP- subsequent discontinuation of TKI therapy in selected
CMLsuggestthatimatinib800mgwasnotassociatedwith patients.93,94,96
lower rates of disease progression than imatinib 400 mg, Therefore,2GTKIsmaybepreferredoverimatinib
despite improved early responses (see Supplementary for younger patients, particularly females since the
TableS2).101–103 Imatinib 800mgwas alsoassociated with achievement of a deep and rapid molecular response
higherratesofdoseinterruption,reduction,ordiscon- mayallowforeventualsafeinterruptionofTKItherapy
tinuation due to grade 3 or 4 adverse events in all of for fertility purposes. Imatinib may be preferred for
the studies. However, patients who could tolerate the older patients with comorbidities, especially cardio-
higherdoseofimatinibachievedhigherresponserates vascularcomorbidities.
thanthosereceivingstandard-doseimatinib.104Imatinib
800mgisnotrecommendedasinitialtherapy,giventhe ToxicityProfile
datashowingsuperiorefficacyof2GTKIsinnewlydiag- All the TKIs are generally well tolerated. Since bosuti-
nosedCP-CML. nib,dasatinib,andnilotinibhaveverygoodefficacyin
Diseaseprogressionismorefrequentinpatientswith theupfrontsetting,differencesintheirpotentialtoxic-
intermediate-orhigh-riskscore,andpreventionofdisease ity profiles may inform the selection of a specific TKI
progressionto AP-CML or BP-CML is the primary goal of asinitialtherapy.Adverseeventsoffirst-lineTKItherapy
TKItherapyinpatientswithCP-CML.2GTKIsareassoci- in patients with CP-CML reported in phase III random-
atedwithalowerriskofdiseaseprogressionthanimatinib izedstudiesarediscussedbelowandaresummarizedin
and are preferred for patients with an intermediate- or SupplementaryTableS4.
high-riskSokalorEuroscore.2GTKIsalsoresultinquicker Nilotinib or bosutinib may be preferred for patients
molecular responses and higher rates of MMR (#0.1% withahistoryoflungdiseaseordeemedtobeatriskfor
BCR::ABL1IS)anddeepmolecularresponse(DMR)(MR4.0 developingpleuraleffusions.Dasatiniborbosutinibmay
[#0.01% BCR::ABL1 IS] or MR4.5 [#0.0032% BCR::ABL1 be preferred in patients with a history of arrhythmias,
IS]) in patients with CP-CML across all risk scores cardiovasculardisease,pancreatitis,orhyperglycemia.
JNCCN.org | Volume22 Issue1 | February2024 51

NCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024
Bosutinib qualityoflifeinpatientswhotakeimatinib.111Hypophos-
In the BFORE study, diarrhea, increased alanine amino- phatemia and decrease in bone mineral density have
transferase, and aspartate aminotransferase were more beennoted in a small group of patients, suggesting that
commonwithbosutinib,whereasmusclespasmsandpe- monitoring bone health should be considered for pa-
ripheral edema were more common with imatinib.94,95 tients taking imatinib.112,113 Skin hypopigmentation has
Grade 3–4 thrombocytopenia was higher with bosutinib also beenreportedas a side effect of imatinib and is re-
and grade 3–4 neutropenia was higher with imatinib. versible on discontinuation or dose reduction.114,115 Re-
Grade3–4anemiawassimilarinbothgroups.Discontinu- versiblerenaldysfunctionwithprolongeduseofimatinib
ation of therapy due to drug-related adverse events oc- hasalsobeenreported.116
curredin14%ofpatientsinthebosutinibgroupcompared
with11%intheimatinibgroup.Increasedalanineamino- Nilotinib
transferase(5%)andincreasedaspartateaminotransferase In the ENESTnd study, rates of nonhematologic adverse
(2%) were the most common adverse eventsleading to eventssuchasnausea,diarrhea,vomiting,musclespasm,
discontinuation of bosutinib. However, there were no and peripheral edema of any grade were higher for pa-
hepatotoxicity-relatedfatalitiesduringthestudy. tients receiving imatinib.Conversely, rash and headache
weremorecommonwithnilotinib.96Grade3or4neutro-
Dasatinib penia was more frequently observed in the imatinib
In the DASISION study, the incidences of grade 3–4 he- group,whereasthrombocytopeniaandanemiaweresim-
matologictoxicities(anemia,neutropenia,andthrombo- ilar in both groups. Electrolyte abnormalities and eleva-
cytopenia) were higher for dasatinib than imatinib.93 tionsinlipase,glucose,andbilirubinweremorefrequent
Nonhematologic adverse events such as muscle spasms, with nilotinib than with imatinib. Patients with a previ-
peripheral edema, and hypophosphatemia were more ous history of pancreatitis may be at greater risk of ele-
frequent with imatinib. Discontinuation of therapy be- vated serum lipase. The overall incidences of adverse
cause of drug-related adverse events occurred in 16% events leading to discontinuation of therapy were com-
and 7% of patients in the dasatinib and imatinib arms, parable in the nilotinib 300 mg twice-daily and imatinib
respectively. Dasatinib is associated with significant but arms (12% and 14%, respectively) and slightly higher in
reversibleinhibitionofplateletaggregationthatmaycon- thenilotinib400mgtwice-dailyarm(20%).
tributetobleedinginsomepatients,especiallyifaccom- Nilotinib labeling contains a black box warning re-
paniedbythrombocytopenia.105 gardingtheriskofQTintervalprolongation,andsudden
Pleuraleffusionwasalsomorecommonwithdasati- cardiacdeathhasbeenreportedinpatientsreceivingni-
nib (28% in the DASISION study compared with ,1% lotinib.110 QT interval prolongation could be managed
withimatiniband33%inadoseoptimizationstudy)and withdosereduction.Electrolyteabnormalitiesshouldbe
agehasbeenidentifiedasasignificantriskfactorforthe corrected before starting treatment with nilotinib, and
development of pleural effusion.106 The occurrence of electrolytesshouldbemonitoredperiodically.Drugsthat
pleural effusion is significantly reduced with dasatinib prolong QT interval should be avoided. Electrocardio-
100mgoncedailycomparedwith70mgtwicedaily.Pa- gram should be obtained to monitor the QT interval at
tients with prior cardiac history, with hypertension, and baseline, 7 days after initiation of nilotinib, and periodi-
receivingdasatinib70mgtwicedailyareatincreasedrisk callythereafter,aswellasafteranydoseadjustments.
of developing pleural effusions.107 Close monitoring and Nilotinibisassociatedwithanincreasedriskofische-
timely intervention are necessary for patients at risk for mic heart disease, ischemic cerebrovascular disease and
developingpleuraleffusions. peripheralarterialocclusivedisease.96The10-yearfollow-
Largely reversible pulmonary arterial hypertension has up data from ENESTnd study showed a higher rate of
been reported as a rare but serious side effect of dasati- cardiovasculareventswithnilotinib(17%and24%,re-
nib.108–110
In the DASISION study, pulmonary hypertension spectively for nilotinib 300 mg twice daily and nilotinib
wasreportedin5%ofpatientstreatedwithdasatinibcom- 400mgtwicedaily)versusimatinib(4%).96Evaluationfor
paredwith,1%ofpatientstreatedwithimatinib.93Evalua- pre-existing cardiovascular risk factors before starting
tionforsignsandsymptomsofunderlyingcardiopulmonary treatmentwithnilotinibandclosemonitoringforanycar-
diseasebeforestartingandduringtreatmentwithdasatinib diovasculareventsduringtreatmentwithnilotinibisrec-
isrecommended.Ifpulmonaryarterialhypertensioniscon- ommended for all patients. Patients with cardiovascular
firmed,dasatinibmustbepermanentlydiscontinued. riskfactorsshouldbereferredtoacardiologist.
Imatinib MonitoringResponsetoTKITherapy
Chronic fatigue (often correlated with musculoskeletal ResponsetoTKItherapyisdeterminedbythemeasure-
painandmuscularcramps)isamajorfactorinreducing mentofhematologic(normalizationofperipheralblood
52 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024

ChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®
counts),cytogenetic(decreaseinthenumberofPh-positive the IS by applying a laboratory-specific conversion
metaphasesusingbonemarrowcytogenetics),andmolecu- factor.17,127
larassessments (decrease in the amount of BCR::ABL1
chimeric mRNA using qPCR). The criteria for hemato- RecommendationsforMonitoringResponseto
logic, cytogenetic, and molecular response are summa- TKITherapy
rizedinCML-D(page46). qPCR(IS)isthepreferredmethodtomonitorresponseto
Conventionalbonemarrowcytogeneticsisthestan- TKI therapy. qPCR assays with a sensitivity of $4.5-log
dardmethodformonitoring cytogeneticresponses,and reduction from the standardized baseline are recom-
many clinical trial response analyses have been based mended to measure BCR::ABL1 transcripts (See CML-E,
onconventionalbonemarrowcytogenetics.Withthead- page 47). In patients with prolonged myelosuppression
vent of qPCR, bone marrow cytogenetic analyses to as- whomaynotbeincompletehematologicresponse(CHR)
sessresponsearerarelyperformed.Ifconventionalbone due to persistent cytopenias or an unexplained drop in
marrow cytogenetics yield no analyzable metaphases, bloodcountsduringtherapy,bonemarrowcytogeneticsis
cytogeneticresponsecanbeevaluatedbyFISH,prefera- indicatedtoconfirmresponsetoTKItherapyandexclude
bly with a dual color probe to minimize false-positive otherpathology,suchasmyelodysplasticsyndromeorthe
rates. FISH and cytogenetic results are correlated, but presence of chromosomal abnormalities other than Ph.
are not
superimposable.117–119
Although some investiga- Giventheriskfortransientmyelosuppressionthatcanoc-
tors have reported that interphase FISH can be used to curduringearlydiseaseresponses,TKItherapyshouldnot
monitor complete cytogenetic response (CCyR), inade- beheldwhilebonemarrowevaluationispending.
quate response to TKI therapy has not been defined on MonitoringwithqPCR(IS)every3monthsisrecom-
thebasisofFISHanalysis.120,121ThepanelfeelsthatFISH mended for all patients after initiating TKI therapy, in-
has been inadequately studied for monitoring response cludingthosewhomeetresponsemilestonesat3,6,and
to TKI therapy and is not generally recommended for 12months(#10%BCR::ABL1ISat3and6months,#1%
monitoringresponseifconventionalcytogeneticsorqPCR BCR::ABL1 IS at 12 months, and #0.1% BCR::ABL1 IS at
areavailable. .12 months). After CCyR (#1% BCR::ABL1 IS) has been
qPCRistheonlytoolcapableofmonitoringresponses achieved, molecular monitoring is recommended every
after the patient has experienced CCyR, since BCR::ABL1 3monthsfor2yearsandevery3to6monthsthereafter.
transcripts typically remain detectable after CCyR is Frequent molecular monitoring with qPCR (IS) can
achieved.AmajoradvantageofqPCRisthestrongcorre- helptoidentifynonadherencetoTKItherapyearlyinthe
lation between the results obtained from the peripheral treatment course.128 Since adherence to TKI therapy is
blood and the bone marrow, allowing for molecular associatedwithbetterclinicaloutcomes,frequentmolec-
monitoringwithoutbonemarrowaspirations.122,123 ular monitoring is essential if there are concerns about
the patient's adherence to TKI therapy. In patients with
StandardizationofMolecularMonitoringUsingtheIS deeper molecular responses (MMR and better) and who
IntheIS,thestandardizedbaseline(definedastheaver- areadherentwithTKItherapy,thefrequencyofmolecu-
age expression of BCR::ABL1 transcripts in 30 patients lar monitoring can be reduced, though the optimal fre-
with untreated CML enrolled in the IRIS trial) is set to quency is unknown. Molecular monitoring of response
100%. Molecular response is expressed as log-reduction to TKI therapy more frequently than every 3 months is
from 100%. For example, a 2-log reduction or greater notpresentlyrecommended.
(#1% BCR::ABL1 IS; MR2.0) generally correlates with
CCyRanda$3-logreduction(#0.1%BCR::ABL1IS)isre- PrognosticSignificanceofCytogeneticand
ferredtoasMMRorMR3.0.17,124,125 MolecularResponse
DMR is defined by the assay's level of sensitivity Earlymolecularresponse(EMR;#10%BCR::ABL1ISat3
(#0.01% BCR::ABL1 [IS], MR4.0; #0.0032% BCR::ABL1 and6months)afterfirst-lineTKItherapyhasemergedas
[IS], MR4.5).126 The sensitivity of a qPCR assay depends an effective prognosticator of favorable long-term PFS
notonlyontheperformanceoftheassay,butalsoonthe andOS(seeSupplementaryTableS5).93,96,103,129Somere-
qualityofagivensample. portssuggestthatEMRat3monthshasasuperiorprog-
As such, the term complete molecular response to nostic value and supports early intervention strategies
denote undetectable BCR::ABL1 transcripts (a negative basedontheBCR::ABL1transcriptlevelat3months.130,131
qPCRtest)shouldbeabandoned,asitmayrefertovery However, other studies yielded partially conflicting re-
differentlevelsofresponse,dependentonthequalityof sults regarding the predictive value of BCR::ABL1 tran-
the sample and sensitivity of the test. Laboratories can scripts at 3 months.132 From a practical perspective, it is
usetheirindividualassays,buttheBCR::ABL1transcripts importanttoconsiderthesedatapointswithintheclini-
obtained in a given laboratory should be converted to cal context. For instance, if BCR::ABL1 transcript level is
JNCCN.org | Volume22 Issue1 | February2024 53

NCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024
minimallyabovethe10%cutoff(eg,11%–15%at3months), available to show that a change of therapy would im-
itisreasonabletoreassessat6monthsbeforeconsidering prove survival, PFS, or EFS in this group of patients.146
majorchangestothetreatmentstrategy. However, the achievement of MMR (#0.1% BCR::ABL1
Somestudieshavesuggestedthattherateofdecline IS)at12monthsisassociatedwithaverylowprobability
in BCR::ABL1 transcripts correlates with longer-term of subsequent loss of response and a high likelihood of
response.133–135 Among patients with .10% BCR::ABL1 experiencing a subsequent DMR (MR4.0; #0.01%
ISafter3monthsoftreatmentwithimatinib,thosewith BCR::ABL1 IS), which may facilitate discontinuation of
a faster decline in BCR::ABL1 (BCR::ABL1 halving time TKI therapy.43,144 In view of the ongoing evolution of
,76days)hadasuperioroutcomecomparedwiththose treatment goals (OS vs treatment-free remission [TFR]),
with a slower decline (4-year PFS rate was 92% vs 63%, expert panels have emphasized the importance of joint
respectively).133 In the German CML IV study, lack of a decision-making between patient and provider, particu-
half-log reduction of BCR::ABL1 transcripts at 3 months larlyinambiguoussituations.147
was associatedwith a higher riskofdisease progression
on imatinib therapy.134 The results of the D-First study ResponseMilestonesAfterFirst-LineTKITherapy
also showed that in patients treated with dasatinib, The most important goals of TKI therapy are to prevent
BCR::ABL1 halving time of 14 days or less was a signifi- disease progression to AP-CML or BP-CML and to
cantpredictorofMMRby12monthsandDMR(MR4.0; achieve either MR2.0 (#1% BCR::ABL1 IS, which corre-
#0.01%BCR::ABL1IS)by18months.135 sponds to CCyR) or MMR (#0.1% BCR::ABL1 IS) within
Achievement of CCyR or #1% BCR::ABL1 IS within 12monthsafterfirst-lineTKItherapy.Theguidelinesem-
12 months after first-line TKI therapy is an established phasize that achievement of response milestones must
prognosticindicatoroflong-termsurvival.136,137IntheIRIS beinterpretedwithintheclinicalcontext,beforemaking
study,the estimated 6-year PFSrate was 97% for patients drastic changes to the treatment strategy, especially in
experiencingaCCyRat6monthscomparedwith80%for ambiguoussituations.
patientswithnocytogeneticresponseat6months.136Inan Thepanelhasincluded#10%BCR::ABL1ISat3and
analysisofpatientswithnewlydiagnosedCP-CMLtreated 6monthsafterinitiationoffirst-lineTKItherapyasare-
with imatinib or 2G TKIs, the 3-year EFS and OS rates sponsemilestone,becausetheachievementofEMRafter
were98%and99%forpatientswhoexperiencedCCyRat first-lineTKItherapyisaneffective prognosticatoroffa-
12monthscomparedwith67%and94%inpatientswho vorable long-term PFS (see CML-3, page 48). Achieve-
didnotexperienceaCCyR.137 ment of .0.1%–1% BCR::ABL1 IS (#1% BCR::ABL1 IS,
MMR(#0.1%BCR::ABL1IS)asapredictorofPFSand which correlates with CCyR) is considered the optimal
OS has also been evaluated in several
studies.122,138–144
In responsemilestoneat12monthsifthegoaloftherapyin
all of these studies, the analyses were done for different an individual patient is long-term survival, whereas the
outcomesmeasuresatmultipletimepoints,butfailedto achievementofMMR(#0.1%BCR::ABL1IS)at12months
adjustformultiplecomparisons,therebyreducingtheva- shouldbeconsideredastheoptimalresponsemilestone
lidity of the conclusions. The general conclusion from ifthe treatmentgoal inanindividual patientis TFR.Pa-
these studies is that the achievement of MMR is associ- tientswhoexperiencetheseresponsemilestonesarecon-
ated with durable long-term cytogenetic remission and sidered to have TKI-sensitive disease, and continuation
lowerrateofdiseaseprogression,butMMRisnotasignif- of the same dose of TKI and assessment of BCR::ABL1
icant predictor of superior OS in patients with a stable transcripts with qPCR (IS) every 3 months is recom-
CCyR.Importantly,withlongerfollow-up,CCyRbecomes mendedforthisgroupofpatients.
an ever-stronger indicator of MMR, reducing the added Inpatientswitha.10%BCR::ABL1ISat3monthsand
prognostic value of MMR. Although the CML IV study .1%BCR::ABL1ISat12months,clinicaljudgmentshould
showed that MR4.5 (#0.0032% BCR::ABL1 IS) at 4 years beused,consideringproblemswithadherence(whichcan
was associated with a significantly higher OS (indepen- becommongivendrugtoxicityatthestartoftherapy),rate
dent of therapy) than MR2.0 (#1% BCR::ABL1 IS, which ofdeclineinBCR::ABL1(thefaster,thebetter),andhowfar
correspondstoCCyR),thisstudydemonstratednosignifi- fromthecutofftheBCR::ABL1valuefalls.Inabilitytoreach
cantdifferencesinOSinpatientswhoexperiencedMMR #10%BCR::ABL1ISat3monthsor #1% BCR::ABL1ISat
(#0.1%BCR::ABL1IS)andthosewhoexperiencedMR2.0 12monthsisassociatedwithahigherriskfordiseasepro-
(#1%BCR::ABL1IS).143 gression. Patients with .10% BCR::ABL1 at 3 months or
The absence of MMR in the presence of a CCyR is .1%BCR::ABL1at12monthscanswitchtoalternateTKI
therefore not considered as an inadequate response to orcontinuethesamedoseofTKI(bosutinib,dasatinib,im-
treatment. Although some investigators have reported atinib,ornilotinib)foranother3months.BCR::ABL1muta-
that dose escalation of imatinib might benefit patients tional analysis and evaluation for allogeneic HCT should
in CCyR with no MMR,145 no randomized studies are be considered. Bone marrow cytogenetics should be
54 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024

ChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®
considered to assess for major cytogenetic response Ponatinib was initially approved as a treatment op-
(MCyR)at3monthsorCCyRat12months. tionforpatientswithaT315Imutationand/orforpatients
Inpatientswith.0.1%–1%BCR::ABL1ISat12months, for whom no other TKI is indicated based on the results
shared decision-making is recommended depending on ofthePACEtrial.160Therecommendedinitialdoseofpo-
thegoaloftherapyinindividualpatients(longer-termsur- natinibwas 45 mg once daily. The high-dose intensity of
vivalvsTFR).Asdiscussedpreviously,althoughnotassoci- ponatinib was associated with increased risk of arterial
ated with increased OS, MMR at 12 months is associated occlusiveevents(AOE)andtheincidenceofcardiovascu-
withalowerrateofdiseaseprogressionandahigherlikeli- lar adverse events was highest among patients with pre-
hood of achieving DMR, which is a prerequisite for TFR. existing cardiovascular risk
factors.160,165–167
In the PACE
Switching toa 2G TKI fromimatinib might be considered trial, serious AOE (cardiovascular, cerebrovascular, and
to increase the probability of achieving MMR (#0.1% peripheral vascular) and venous thromboembolic events
BCR::ABL1IS)at12months.However,thereisapossibility occurred in 31% and 6% of patients, respectively.160 Car-
thataswitchmaybeassociatedwithincreasedtoxicity. diovascular, cerebrovascular, and peripheral AOEs were
Referral to specialized CML centers and/or enrollment reportedin16%,13%,and14%ofpatients,respectively.
inaclinicaltrialshouldbeconsidered. IntheOPTICtrialthatevaluatedthesafetyandeffi-
Patientswith.10%BCR::ABL1ISat6and12months cacy of response-adjusted dosing regimens, patients
are considered to have TKI-resistant disease. Evaluation were randomized to ponatinib starting doses of 45 mg,
for allogeneic HCT (ie, a discussion with a transplant 30mg,and15mg,withdosereductionto15mgwithex-
specialist, which might include HLA testing) is recom- perienceof#1%BCR::ABL1(IS)inthe45mgand30mg
mended. Bone marrow cytogenetic analysis to assess cohorts.161 Ponatinib was effective at all 3 dose levels
ACAs should be considered. Alternative treatment op- (45mg,30mg,and15mg)andthemaximumbenefitwas
tionsshouldbeconsideredasdescribedsubsequently. observed with 45 mg. After a median follow-up of
32months,BCR::ABL1(IS)#1%at12monthswasachieved
Second-LineTherapy in 44% of patients in the 45 mg cohort compared with
Dose escalationofimatinib upto800mg dailyhas been 29% and 23% in the 30 mg and 15 mg cohorts, respec-
showntoovercomesomecasesofprimaryresistanceand tively. After response-based dose reduction to 15 mg, re-
isparticularlyeffectiveforcytogeneticrelapseinpatients sponses were maintained in 73% and 79% of patients in
whohadexperiencedcytogeneticresponsewithimatinib the45mgand30mgcohorts,respectively.Therateofany
400mgdaily,althoughthedurationofresponseshastypi- AOEreportedintheOPTICtrial(10%inthe45mgcohort;
cally been short.148–151 However, it is unlikely to benefit 5%and3%inthe30mgand15mgcohorts,respectively)
patientswhodonotexperiencehematologicresponseor was lower than that reported for ponatinib 45 mg in the
thosewhoneverhadacytogeneticresponsewithimatinib PACE trial. Based on the results of the OPTIC trial, the
400 mg daily. In patients with .10% BCR::ABL1 IS at FDA has approved a response-adjusted dosing regimen
3monthsafterimatinib400mg,switchingtonilotinibor forponatinib(startingdoseof45mgoncedailywithare-
dasatinib has been shown to result in higher rates of ductionto15mgonachievementofBCR::ABL1[IS]#1%)
MMRat12monthsthandoseescalationofimatinib.152–154
for patients with CP-CML with resistance or intolerance
Although dose escalation of imatinib has been shown to to$2priorkinaseinhibitors.
bebeneficialforpatientsinCCyRwithoutMMR,noran- Cardiovascular risk factors (eg, diabetes mellitus, hy-
domized studies have shown that a change of therapy pertension,hyperlipidemia,smoking,estrogenuse)should
wouldimprovePFSorEFSinthisgroupofpatients.145,146 beidentifiedandcontrolledbeforestartingponatinib.Pa-
Dasatinib, nilotinib, and bosutinib, which are more tients should be monitored for high blood pressure, evi-
potent than imatinib in vitro and retain activity against denceofarterialocclusiveorthromboembolicevents,and
manyoftheimatinib-resistantBCR::ABL1kinasedomain reduced cardiac function.168 Ponatinib should be inter-
mutantsexceptT315I,areeffectivetreatmentoptionsfor ruptedorstoppedimmediatelyforvascularocclusionand
patientswhoareintoleranttoimatiniborCP-CMLthatis forneworworseningheartfailure.Patientswithcardiovas-
resistant to
imatinib.155–157
Bosutinib also has shown ac- cularriskfactorsshouldbereferredtoacardiologist.Asci-
tivityinpatientswithCP-CMLthatisresistanttomultiple minib is approved for patients with CP-CML having the
TKIs (imatinib, dasatinib, and nilotinib).158,159 Ponatinib T315Imutationand/orCP-CMLwithresistanceorintoler-
and asciminib (specifically targeting the ABL myristoyl anceto$2priorTKIs.
pocket inhibitor) are active against most of the resistant InthephaseIIIrandomizedstudy(ASCEMBL),asci-
BCR::ABL1kinasedomainmutantsincludingT315I.160–164
minib 40 mg twice daily achieved higher molecular re-
Long-termefficacydatafromclinicaltrialsonsecond- sponse rates (MMR, MR4.0, and MR4.5) than bosutinib
lineandsubsequentTKItherapyforCP-CMLaresumma- 500 mg once daily in patients with CP-CML previously
rizedinSupplementaryTableS6. treated with $2 prior TKIs. The incidence of adverse
JNCCN.org | Volume22 Issue1 | February2024 55

NCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024
events leading to treatment discontinuation was also EMR (#10% BCR::ABL1 IS at 3 and 6 months) after
lower with asciminib (6% vs 21%).163,164 Gastrointestinal second-line TKI therapy with dasatinib or nilotinib has
toxicities(diarrhea,nausea,andvomiting)andbiochemi- alsobeenreportedtobeaprognosticatorofOSandPFS
calabnormalities(increasedalanineaminotransferaseand (see Supplementary Table S7).155,156 Patients who do not
aspartate aminotransferase levels) were notably higher experiencecytogeneticormolecularresponsesat3,6,or
with bosutinib. AOEs were reported in 3% and 1% of pa- 12monthsaftersecond-lineandsubsequentTKItherapy
tients treated with asciminib and bosutinib, respectively. should be considered for alternative therapies or alloge-
Patientswithahistoryofcardiovascularriskfactorsorcar- neicHCTifdeemedeligible.
diovascularsignsandsymptomsshouldbecarefullymoni- BCR::ABL1 kinase domain mutation analysis (see later
tored, and appropriate treatment should be started as section),evaluationofdruginteractions,andcomplianceto
clinicallyindicated.Therecommendedinitialdoseofasci- therapy are recommended before the start of second-line
minibis80mgoncedailyor40mgtwicedailyinpatients TKItherapy.Asdiscussedearlier,myeloidmutationalanaly-
without a T315I mutation and 200 mg twice daily for pa- sisusingNGStoidentifyBCR::ABL1–independentmutations
tients with a T315I mutation. In the phase I study, most mayalsobeusefulforpatientswithCP-CMLwhodonotex-
patients with a T315I mutation experiencing CCyR and perienceoptimalresponsemilestonesduetothepresence
MMRhadreceived.150mgtwice-dailyasciminib.162 ofcytopeniasandforthosewithTKIresistantdisease.
Omacetaxine is a treatment option for patients with
CP-CML resistant or intolerant to $2 TKIs including DrugInteractions
those witha T315Imutation.169,170 Omacetaxine resulted AllTKIsaremetabolizedintheliverbycytochromeP450
in MCyR, CCyR, and MMR rates of 23%, 16%, and 17%, (CYP) enzymes, and concomitant use of drugs that in-
respectively.TheT315Iclonedeclinedtobelowdetection duce or inhibit CYP3A4 or CYP3A5 enzymes may alter
limits in 61% of patients with CP-CML resistant to prior thetherapeuticeffectofTKIs.172,173
TKI therapy and the T315I mutation (CML 202 study; DrugsthatareCYP3A4orCYP3A5inducersmayde-
n562).169ThemedianPFSwas8monthsandthemedian crease the therapeutic plasma concentration of TKIs,
OS had not yet been reached. In the cohort of patients whereas CYP3A4 inhibitors and drugs that are metabo-
withCP-CMLresistantorintolerantto$2TKIs(CML203 lized by the CYP3A4 or CYP3A5 enzyme might result in
study; n546), the MCyR and CCyR rates were 22% and increased plasma levels of TKIs. In addition, imatinib is
4%,respectively.ThemedianPFSandOSwere7months also a weak inhibitor of the CYP2D6 and CYP2C9 isoen-
and 30 months, respectively.170 The response rates and zymesandnilotinibisacompetitiveinhibitorofCYP2C8,
survival outcomes, however, were substantially lower CYP2C9, CYP2D6, and UGT1A1, potentially increasing
than those observed with ponatinib in the PACE trial. the plasma concentrations of drugs eliminated by these
Omacetaxine had an acceptable toxicity profile, and the enzymes. Asciminibis also a CYP2C9 inhibitor and con-
most common grade 3–4 adverse events were thrombo- comitantuse ofasciminib increases the plasmaconcen-
cytopenia(67%),neutropenia(47%),andanemia(37%). trationofotherdrugsthatareCYP2C9substrates.
Concomitant use of drugs metabolized by these
ClinicalConsiderationsfortheSelectionof enzymes requires caution, and appropriate alternatives
Second-LineTKITherapy should be explored to optimize treatment outcome. If
Switching to a 2G TKI (based on the BCR::ABL1 kinase coadministration cannot be avoided, dose modification
domain mutation status) is recommended for patients shouldbeconsidered.
withdiseasethatisresistanttoimatinib400mgdaily.
Patients with disease that is resistant to bosutinib, AdherencetoTherapy
dasatinib, or nilotinib could be switched to an alternate Treatment interruptions and nonadherence to therapy
2G TKI. However, there is no clear evidence to support may lead to undesirable clinical
outcomes.174–176
In the
thatswitchingtoalternate2GTKItherapywouldimprove ADAGIOstudy,nonadherencetoimatinibwasassociated
long-term clinical outcome for this group of patients.171 withpoorerresponse.Patientswithsuboptimalresponse
Subsequent therapy with an alternate 2G TKI is ex- missedsignificantlymoreimatinibdoses(23%)thandid
pectedtobeeffectiveonlyinpatientswithidentifiable thosewithoptimalresponse(7%).174Adherencetoimati-
BCR::ABL1 mutations that confer resistance to TKI nibtherapyhasbeenidentifiedastheonlyindependent
therapy. Ponatinib is the preferred treatment option predictor for achieving complete molecular response on
forpatientswithaT315Imutationinanyphase.Pona- standard-dose imatinib.175 The 6-year probability of
tinib is also preferred for patients with no identifiable experiencingcompletemolecularresponsewassignifi-
BCR::ABL1mutations.EvaluationofallogeneicHCTor cantly higher for patients with .90% adherence rate
enrollment in a clinical trial should be considered for (44%comparedwith0%forpatientswith#90%adher-
thisgroupofpatients. encerate;P5.002).175Pooradherencetoimatinibtherapy
56 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024

ChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®
hasalsobeenidentifiedasthemostimportantfactorcon- to imatinib, dasatinib, nilotinib, and bosutinib.202,203 The
tributingtocytogeneticrelapseandinadequateresponse T315A, F317L/I/V/C, and V299L mutants are resistant to
toimatinib.176Patientswithadherenceof85%orlesshad dasatinibandtheE255K/V,F359V/C,andY253Hmutants
ahigherprobabilityoflosingCCyRat2years thanthose are resistant to
nilotinib.200,204–206
The G250E and V299L
withadherenceofgreaterthan85%(27%and2%,respec- mutantsareresistanttobosutinib.158
tively).Pooradherencetotherapyhasalsobeenreported Bosutinib and dasatinib have demonstrated activity
inpatientsreceivingdasatinibandnilotinibfollowingin- inpatientswithBCR::ABL1mutantsresistanttonilotinib
adequateresponsetoimatinib.177,178 (Y253H, E255K/V, and F359C/I/V).158,206 Bosutinib has
Patient education on adherence to therapy and close minimalactivityagainsttheF317Lmutation(whichisre-
monitoringofeachpatient’sadherenceiscriticaltoachiev- sistant to dasatinib) and nilotinib maybepreferred over
ing optimal responses. In a significant proportion of pa- bosutinib in patients with the F317L mutation.200,205,207
tients with TKI-induced toxicities, responses have been Ponatinib is active against BCR::ABL1 mutants resistant
observed with doses well below their determined maxi- todasatinibornilotinib,includingE255V,Y253H,F359V,
mumtolerateddoses.179Shortinterruptionsordosereduc- andT315I.160Therearenotenoughdataavailableregard-
tions,whenmedicallynecessary,maynothaveanegative ingtheimpactofmutationsontheefficacyofasciminib
impactondiseasecontrolorotheroutcomes. because of the heterogeneity of reported mutations and
Adequateandappropriatemanagementofsideeffects low patient numbers in the ASCEMBL trial.163 Patients
and scheduling appropriate follow-up visits to review side withdetectablebosutinib-resistantBCR::ABL1mutations
effectsmaybehelpfultoimprovepatientadherenceto (T315I or V299L) were ineligible to participate in this
therapy.180SwitchingtoanalternateTKIbecauseofin- trial.163InadditiontoT315I,asciminibhasbeenreported
tolerance is appropriate for patients with disease re- tobeactiveagainstselectBCR::ABL1mutantsresistantto
sponding to TKI therapy and it might be beneficial for bosutinib,dasatinib,ornilotinib(G250E,Y253H,E255V).
selected patients with acute grade 3–4 nonhematologic However,F359V/I/Cmutationsareinsensitivetoascimi-
toxicitiesorinthose with chronic, low-grade nonhema- nib.208 Although new myristoyl-pocket mutations have
tologictoxicitiesthatarenotmanageablewithadequate beendetectedduringasciminibtreatment,thereisinsuf-
supportivecaremeasures.181,182 ficientdatatodeterminetheirsignificance.
BCR::ABL1 compound mutations (variants containing
ResistancetoTKITherapy $2 mutations within the same BCR::ABL1 allele that pre-
Aberrant expressions of drug
transporters183–185
and sumably arise sequentially) confer different levels of resis-
plasma protein binding of
TKI186–188
could contribute to tance to TKI therapy, and compound mutants involving
primaryresistancebyalteringtheintracellularandplasma T315I confer the highest level of resistance to all TKIs, in-
concentrationofTKI. cludingponatinib.209,210InanotherstudythatusedNGSto
Pretreatment levels of organic cation transporter 1 detect low-level and BCR::ABL1 compound mutations in
(OCT1)havebeenreportedasthemostpowerfulpredic- 267 patients with heavily pretreated CP-CML from the
torofresponsetoimatinib.189Conversely,cellularuptake PACEtrial,nocompoundmutationwasidentifiedthatcon-
of dasatinib or nilotinib seems to be independent of sistently conferred resistance to ponatinib, suggesting that
OCT1expression,suggestingthatpatientswithlowOCT1 suchcompoundmutationsareuncommonfollowingtreat-
expressionmighthavebetteroutcomeswithdasatinibor mentwithbosutinib,dasatinib,ornilotinibforCP-CML.211
nilotinibthanwithimatinib.190–193 BCR::ABL135INS has been associated with resistance
Monitoring imatinib plasma levels may be useful in to imatinib.212,213 In one study, BCR::ABL135INS was de-
determining patient adherence to therapy. However, tectedin23%ofpatients(64ofthe284patients;45patients
therearenodatatosupportthatchangeoftherapybased with CP-CML).213 Among the 34 patients with CP-CML
onplasmaimatiniblevelswillaffecttreatmentoutcomes, treated with imatinib, primary refractory disease, disease
and assays that measure plasma levels of imatinib are progression while on imatinib and disease progression
notwidelyavailable. after dose interruption were reported in 24% (n58),
32% (n511), and 12% (n54) of patients respectively.
BCR::ABL1KinaseDomainMutationAnalysis BCR::ABL135INSwasalsoassociatedwithgrade3or4he-
Point mutations in the BCR::ABL1 kinase domain are a matologictoxicity.Thisstudy,however,wasnotpowered
frequentmechanismofsecondaryresistancetoTKIther-
todeterminetheefficacyof2GTKIagainstBCR-ABL135INS
apyandareassociatedwithpoorprognosisandahigher sinceveryfewpatientswiththismutationreceivedeither
riskofdiseaseprogression.194–199E255K/V,F359C/V,Y253H,
dasatinibornilotinib.
and T315I mutants are most commonly associated with BCR::ABL1 kinase domain mutational analysis is
diseaseprogressionandrelapse.200,201AmongtheBCR::ABL1 helpful in the selection of subsequent TKI therapy for
kinasedomainmutations,T315Iconferscompleteresistance patients with inadequate initial response to first-line or
JNCCN.org | Volume22 Issue1 | February2024 57

NCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024
second-line TKI therapy.214 The guidelines recommend ($MR4.0; #0.01% BCR::ABL1 IS) for 2 or more years has
BCR::ABL1 kinase domain mutational analysis for pa- been evaluated in several clinical
studies.220–234
Longer-
tientswhodonotachieveresponsemilestones,forthose termfollow-updatafromtheTKIdiscontinuationtrialsare
withanysignoflossofresponse(hematologicorcytoge- summarizedinSupplementaryTableS8.
neticrelapse),andifthereisa1-logincreaseinBCR::ABL1 The results of the RE-STIM study showed the safety
levelwithlossofMMR. ofasecondTKIdiscontinuationafterafirstunsuccessful
BCR::ABL1 kinase domain mutational analysis pro- attempt.235TherateofmolecularrelapseafterthefirstTKI
vides additional guidance for selecting subsequent TKI discontinuation attempt was the only factor significantly
therapy only in patients with identifiable mutations. associated with outcome. The TFR rate 24 months after
Treatment options based on BCR::ABL1 kinase domain the second TKI discontinuation was higher for patients
mutationstatusareoutlinedonCML-5(page49).Inpa- whoremainedinDMRwithinthefirst3monthsafterthe
tients with no identifiable mutations, the selection of firstTKIdiscontinuation(72%vs32%forotherpatients).
subsequentTKItherapyshouldbebasedonthepatient’s Approximately40%–60%ofpatientswhodiscontinue
age, ability to tolerate therapy, presence of comorbid TKI therapy after achieving DMR experience recurrence
conditions,andtoxicityprofileoftheTKI. within 12 months of treatment cessation, in some cases
asearlyas1monthafterdiscontinuationofTKItherapy.
RisingBCR::ABL1Transcripts Severalfactorsmayhelppredicttheriskofrecurrenceaf-
Rising BCR::ABL1 transcripts are associated with an in- terTKIdiscontinuation(ahigherSokalriskscore,female
creased likelihood of detecting BCR::ABL1 kinase domain gender, lower natural killer cell counts, suboptimal re-
mutationsandcytogeneticrelapse.215–219Inpatientswhohad
sponseorresistancetoimatinib,durationofTKItherapy,
experiencedverylowlevelsofBCR::ABL1transcripts,emer- andDMRbeforeTKIdiscontinuation).However,onlythe
genceofBCR::ABL1kinasedomainmutationswasmorefre- durationofTKItherapyandDMRbeforediscontinuation
quent in those who had a .2-fold increase in BCR::ABL1 of TKI therapy have been associated with TFR with a
transcripts compared with those with stable or decreasing highlevelofconsistency.220,225,229,230
BCR::ABL1transcripts.215Aserialrisehasbeenreportedtobe IntheEURO-SKIstudy,durationoftreatmentwithima-
more reliable than a single $2-fold increase in BCR::ABL1 tinib ($6 years) and duration of DMR (MR4.0 for 3 years)
transcripts.216,217 Among patients in CCyR with a $0.5-log were significantly associated with MMR maintenance at
increaseinBCR::ABL1transcriptsonatleast2occasions,the 6monthsafterdiscontinuationofimatinibandlackof
highest risk of disease progression was associated with loss MR4.0 at 36 months after discontinuation ofTKItherapy
ofMMRand.1-logincreaseinBCR::ABL1transcripts.217 was highly predictive of subsequent loss of MMR.229,236 A
Risingtranscriptlevelsshouldpromptaninvestigation rapidinitialdeclineinBCR::ABL1transcriptsafterinitiation
of treatment adherence and reassessment of coadminis- offirst-lineTKItherapyhasalsobeenshowntobeaninde-
teredmedications.ThepreciseincreaseinBCR::ABL1tran- pendentpredictorofTFReligibilityandsustainedTFR.237
scripts that warrants a mutation analysis depends on the ResumptionofTKItherapyimmediatelyafterrecur-
performance characteristics of the qPCR assay.219 Some renceresultsintheachievementofDMRinalmostallpa-
laboratories have advocated a 2- to 3-fold range,141,218,219 tients. In the STIM study, molecular relapse (trigger to
whileothershavetakenamoreconservativeapproach resume TKI therapy) was defined as positivity for
(5- to 10-fold).217 Obviously, some common sense must BCR::ABL1 transcripts by qPCR confirmed by a 1-log in-
prevail, since the amount of change in absolute terms de- creaseinBCR::ABL1transcriptsbetween2successiveas-
pends on the level of molecular response. For example, a sessmentsorlossofMMRatonepoint.220,221 Theresults
finding of any BCR::ABL1 after achieving a DMR (MR4.5; of the A-STIM study showed that loss of MMR (#0.1%
#0.0032%BCR::ABL1IS)isaninfiniteincreaseinBCR::ABL1 BCR::ABL1 IS) could be used as a practical criterion for
transcripts.However,achangeinBCR::ABL1transcriptsfrom restartingTKItherapy.TheestimatedprobabilityofMMR
abarelydetectableleveltoMR4.5isclearlydifferentfroma loss was 35% at 12 months and 36% at 24 months after
5-foldincreaseinBCR::ABL1transcriptsafterachievingMMR. discontinuationofimatinib.223
Currentlytherearenospecificguidelinesforchang- TKIwithdrawalsyndrome(aggravationornewdevel-
ingtherapyonlybasedonrisingBCR::ABL1levelsasde- opmentofmusculoskeletalpainand/orpruritusafterdis-
tected by qPCR, and it should be done only in the continuationofTKItherapy)hasbeenreportedduringthe
contextofaclinicaltrial. TFRperiodinsomeTKIdiscontinuationstudies.225,230,232,233
The occurrence of imatinib withdrawal syndrome was
DiscontinuationofTKITherapy associated with a lower rate of molecular relapse in the
ThefeasibilityofdiscontinuationofTKItherapy(dasatinib, KIDstudy.225
imatinib,ornilotinib)withclosemonitoringincarefullyse- The feasibility of TFR after discontinuation of TKIs
lectedpatientswhohaveexeriencedandmaintainedDMR other than dasatinib, imatinib, or nilotinib has not yet
58 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024

ChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®
beenevaluatedinclinicalstudies.IntheEURO-SKIstudy from selected studies are outlined in Supplementary
thatevaluatedTFRafterdiscontinuationofanyfirst-line TableS9andSupplementaryTableS10.
TKI therapy (imatinib, dasatinib, or nilotinib) in eligible
patients,thetypeoffirst-lineTKItherapydidnotsignifi- Bosutinib
cantlyaffectmolecularrelapse-freesurvival.229Therefore, The recommended starting dose of bosutinib is 400 mg
itisreasonabletoassumethatthelikelihoodofTFRafter daily for patients with newly diagnosed CP-CML (which
discontinuation would be similar irrespective of TKI in is better tolerated than the 500 mg daily dose that was
patients who have experienced and maintained DMR usedintheinitialrandomizedphaseIIItrial)and500mg
(MR4.0;#0.01%BCR::ABL1IS)for2ormoreyears. oncedailyforintolerantorresistantCP-CML.
Clinicalstudiesthathaveevaluatedthesafetyandef- InpatientswithnewlydiagnosedCP-CML,recommen-
ficacyofdiscontinuationofTKIhaveusedstricteligibility dationsfromanexpertpanelsuggestinitiatingbosutinibat
criteria and have mandated more frequent molecular 200to300mgoncedaily(withdoseescalationasclinically
monitoring than typically recommended for patients on indicated)inmostpatientsandinitiationat400mgdailyis
TKItherapy.AccesstoareliableqPCR(IS)withasensitiv- recommended only for patients with high-risk disease.238
ity of detection of at least MR4.5 (BCR::ABL1 #0.0032% Theresultsofaretrospectiveanalysissuggestthatdosere-
IS) and the availability of test results within 2 weeks is ductionofbosutinibto300mgor400mgresultsinbetter
oneofthekeyrequirementstomonitorpatientsafterdis- tolerabilityandimprovedefficacyinpatientswithCP-CML
continuationofTKItherapyandascertaintheirsafety. resistantimatinib,dasatiniband/ornilotinib.239
Based on available evidence from clinical studies
thathaveevaluatedthefeasibilityofTFR,thepanelmem- Dasatinib
bers feel that discontinuation of TKI therapy (with close The recommended starting dose of dasatinib is 100 mg
monitoring) is feasible in carefully selected, consenting oncedailyforpatientswithCP-CML.
patients(inearlyCP-CML)whohaveachievedandmain- Long-term follow-up of a single-arm study (81 evalu-
tained a DMR ($MR4.0) for 2 or more years. The panel ablepatients)suggeststhatdasatinib50mgoncedailymay
acknowledges that more frequent molecular monitoring havesimilarefficacyinpatientswithlow-orintermediate-
is essential following discontinuation of TKI therapy for risk CP-CML.240,241 Dasatinib 20 mg once daily has also
theearlyidentificationoflossofMMR.Frequencyofmo- beenshowntobeanappropriatestartingdoseforpatients
lecularmonitoringhasvariedsubstantiallyamongdiffer- 65yearsandoverwithnewlydiagnosedCP-CML.242,243In-
ent studies, and the optimal frequency of molecular termittentdosing(on/offtreatmentwithadrugholiday)or
monitoring in patients with a loss of MMR after dis- dosereductionto50mgoncedailyhasalsobeenshownto
continuationofTKItherapyhasnotbeenestablished. beeffectiveassecond-lineandsubsequenttherapyinpa-
The criteria for the selection of patients suitable for
tientswithCP-CMLresistant/intoleranttoimatinib.244–247
discontinuationofTKItherapyandrecommendationsfor Dasatinibat50mg(20mgwithcarefulmonitoringin
molecularmonitoringinTFRphaseareoutlinedonCML- selectedpatients)shouldbeconsideredforpatientswith
F(page50).Thepanelemphasizesthatdiscontinuationof clinicallysignificantintolerancetodasatinib100mgonce
TKItherapyoutsideofaclinicaltrialshouldbeconsidered dailytoavoidseriousadverseevents(eg,pleuraleffusion,
onlyifall thecriteriaincludedonthelistaremet. myelosuppression), necessitating the discontinuation of
dasatinib.
DoseModificationsofTKITherapy
Limited available evidence (mostly from nonrandomized Imatinib
studiesandretrospectiveanalysis)suggeststhatinitiationof The recommended starting dose of imatinib is 400 mg
TKIs(bosutinib,dasatinib,nilotinib)atlowerdosesand/or oncedailyforpatientswithCP-CML.
de-escalationforallTKIs(withclosemonitoring)inpatients InaphaseIIstudythatevaluatedimatinib400mgin
who achieve optimal responses are appropriate strategies 481 patients with newly diagnosed CML, dose reduction
for the prevention and management of treatment-related wasrequiredin46%ofpatientsduetointoleranceandex-
adverseeventsandtoavoidlong-termtoxicities.However, cessivedosereductionstolessthan300mgwasassociated
except for ponatinib (OPTIC trial), the minimum effective withinferiorresponseratesandsurvivaloutcomes.248
doseoroptimalde-escalationofTKIhasnotyetbeenestab-
lishedinprospectivephaseIIIrandomizedclinicaltrials. Nilotinib
The recommended starting dose of nilotinib is 300 mg
InitiationofTKIsatLowerDose twicedailyforpatientswithnewlydiagnosedCP-CMLand
Low-doseTKIsforfirst-lineordosemodificationsforin- 400mgtwicedailyforresistantorintolerantCP-CML.
tolerance or resistance have been evaluated mostly in In a retrospective analysis of 70 patients with newly
nonrandomizedstudiesandretrospectiveanalyses.Data diagnosed CP-CML, early dose reduction of nilotinib to
JNCCN.org | Volume22 Issue1 | February2024 59

NCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024
less than 600 mg/day resulted in a lowerrate of adverse reduceddosenilotinib(oncedaily)inpatientsexperiencing
events and bettertherapeuticefficacy.249 One-year MMR MMRonstandard-dosenilotinib(twicedaily).
and overall MR4.5 rates were 90% and 60%, respectively
for the 10 patients treated with 600 mg/day of nilotinib Management of CML During Pregnancy and
throughoutthestudy,withnodiseaseprogressiontoad- Breastfeeding
vancedphase. Themedianageofdiseaseonsetis65years,butCMLoc-
TheENESTswiftstudyshowedthatswitchingtonilo- cursinallagegroups.TheEUTOSpopulation-basedreg-
tinib300mgtwicedaily(whichislowerthantherecom- istryhasreportedthatapproximately37%ofpatientsare
mendeddoseof400mgdailyinthesecond-linesetting) of reproductive age at diagnosis.260 Clinical care teams
was effective and well-tolerated in most patients with should be prepared to address issues relating to fertility
CP-CML withintolerancetoimatinibor dasatinibinthe and pregnancy as well as counsel these patients about
first-linesetting.250 thepotentialrisksandbenefitsoftreatmentdiscontinua-
tionandpossibleresumptionofTKItherapyshouldCML
Ponatinib recurduringpregnancy.
The recommended initial dose of ponatinib is 45 mg
oncedaily. TKITherapyandConception
IntheOPTICtrial,theoptimalbenefitwasobserved TKI therapy appears to affect some male hormones at
with 45 mg once daily for all patients including those leasttransiently,butitdoesnotappeartohaveadeleteri-
with the T315I mutation. Ponatinib at lower dose levels ouseffectonmalefertility.Furthermore,themiscarriage
(30mgoncedailyand15mgoncedaily)resultedinclini- or fetal abnormality rate is not elevated in female part-
cal benefit in patients without the T315I mutation (see
nersofmalesonTKItherapy.261–265
Supplementary Table S6). These data support initiation TKI therapy during pregnancy has been associated
of ponatinib at 45 mg once daily for patients with the with both a higher rate of miscarriage and fetal abnor-
T315I mutation followed by dose reduction to 15 mg
malities.266–271
In one report on the outcome of pregnan-
oncedailyonachievementofBCR::ABL1(IS)#1%.161 ciesin180patientsexposedtoimatinibduringpregnancy,
50% of pregnancies with known outcome were normal
The results of a retrospective analysis showed that
and10%ofpregnancieswithknownoutcomehadfetalab-
ponatinib 15 mg daily was associated with a lower inci-
normalities.266 Eighteen pregnancies ended in spontane-
dence of drug-relatedadverseevents with no impact on
efficacy.251 ous abortion. In another report on the outcomes of
pregnancy and conception during treatment with dasati-
nib,among46patientstreatedwithdasatinib,15patients
De-escalationorIntermittentDosingofTKI (33%)deliveredanormalinfant.267Electiveorspontaneous
TKI de-escalation has been shown to be feasible in pa- abortionswerereportedin18(39%)and8patients(17%),
tients, primarily those without prior TKI resistance, who respectively, and 5 patients (11%) had an abnormal preg-
hadreceivedTKItherapyfor2 or moreyearswithdura- nancy. Fetal abnormalities were reported in 7 cases.
bleMMRorDMRfor12ormoremonths.252–259
Among33patientswhoconceivedwithmaleswhohadre-
Data from selected clinical trials that have evaluated ceivedtreatmentwithdasatinib,30(91%)deliveredinfants
thisapproacharesummarizedinSupplementaryTableS11. who were normal at birth. In a report of 16 pregnancy
ThephaseIIINTERIMstudyfirstestablishedthatin-
casesamongpatientsassignedfemaleatbirthtreatedwith
termittentdosingofimatinibisfeasibleinpatients65years bosutinibnoted6livebirths,4abortions,and6unknown
and over in stable MMR or MR4, after 2or more years outcomes.272
of treatment.252 The interim analysis of the phase III Althoughthereisapaucityofdataregardingtheout-
OPTkIMA study demonstrated that this approach is also comeofpregnancyinpatientsreceivingbosutinib,ponati-
feasible for patients treated with dasatinib or nilotinib.259 nib, or asciminib at conception, all TKIs also must be
OPTkIMAisanongoingstudythatisevaluatingthepoten- considered unsafe for use during pregnancy. Conception
tialde-escalationofallTKIsafterachievingastableDMR. whileonactiveTKItherapyisstronglydiscourageddueto
TheDESTINYtrialshowedthefeasibilityofde-escalating the risk of fetal abnormalities. Close monitoring and
TKIs (imatinib, dasatinib, or nilotinib) to half the standard promptconsiderationofholdingTKItherapy(ifpregnancy
dose for 12 months (imatinib 200 mg once daily; dasatinib occurswhileonTKItherapy)shouldbeconsidered.
50mgoncedaily,ornilotinib200mgtwicedaily)inpatients Dependingonotherfactorssuchasage,anaturalpreg-
achieving MMR or MR4 followed by discontinuation for nancy may occur months after stopping TKI therapy.273,274
24months(withfrequentmonitoring).255,256 A prolonged washout period before pregnancy should be
TheNILO-REDstudy(publishedonlyasanabstract) considered,althoughtherearenodataregardinghowlong
demonstrated the feasibility of maintenance therapy with apatientshouldbeoffTKItherapybeforetryingtobecome
60 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024

ChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®
pregnant.Therearenopublishedguidelinesregardingthe regarding how best to monitor CML during pregnancy,
optimal depth of molecular response that is considered nor how best to manage progressive disease should it
“safe”tostopTKItherapybeforeattemptingpregnancy.275 occur during pregnancy. Referral to a CML specialty
Discontinuation of TKI therapy because of preg- centerandconsultationwithahigh-riskobstetricianis
nancyinpatientsassignedfemaleatbirthwhowerenot recommended.
in DMR (#0.01% BCR::ABL1 IS) has only been reported
in a small series of patients.273,274,276,277 In one series,
TreatmentDuringPregnancy
among10patientswhostoppedimatinibbecauseofpreg-
Most of the literature regarding treatment during preg-
nancyafteramedianof8monthsoftherapy,5ofthe9pa-
nancy consists of case reports. TKI therapy, particularly
tientswhohadexperiencedaCHRlosttheresponseafter
stopping therapy, and 6 had an increase in Ph-positive during the first trimester, should be avoided because of
metaphases.273 At 18 months after resuming therapy, all teratogenicrisk.IfTKItherapyisconsideredduringpreg-
9patientshadachievedaCHRbutonly3femalesexperi- nancy, the potential benefit for the mother and the po-
encedaCCyRandnonehadexperiencedanMMR.Inan- tential riskto the fetus of continuing TKI therapy versus
otherseriesthatreportedtheoutcomesfor7patientswho the risk of treatment interruption leading to the loss of
were not in DMR at the time imatinib was stopped be- optimaldiseaseresponsemustbecarefullyevaluatedon
cause of pregnancy, 3 were in an MMR.274 All 7 patients anindividualbasis.
haddiseaserelapse.The3whohadanMMRatthetime Leukapheresis can be used for a rising white blood
imatinib was stopped could regain the same response cell count and/or platelet count, although there are no
once the drug was restarted, whereas the remaining 4 datathatrecommendatwhatlevelleukapheresisand/or
patientsdidnot.
plateletpheresisshouldbeinitiated.278–281Low-doseaspi-
rin or low-molecular-weight heparin can be considered
PlanningaPregnancy forpatientswiththrombocytosis.282,283
In patients assigned male at birth, the general recom- The panel also recommends against the use of
mendationisthatTKItherapyneednotbediscontinued hydroxyurea during pregnancy, especially in the first
ifapregnancyisplanned.However,experienceislimited.
trimester.284–286
If treatment is needed during preg-
Sperm banking can also be performed before starting nancy, it is preferable to initiate treatment with inter-
TKI therapy, but no data are available regarding quality feron alfa-2a.287 Most data using interferons during
ofsperminmaleswithuntreatedCML. pregnancyhavebeenreportedinpatientswithessential
In patients assigned female at birth, due to the risk thrombocythemia.288,289Ifintroducedearlier,interferons
ofmiscarriageandfetalabnormalitiesduringpregnancy, can preserve molecular remission after discontinuation
TKI therapy should be stopped prior to natural concep- of TKI.290,291 Peginterferon alfa-2a is the only interferon
tion and patients should remain off therapy during availableforclinicaluseintheUnitedStates.
pregnancy.266–268
Monthly monitoring of complete blood count with
Fertilitypreservationshouldbediscussedwithallpa- differential and frequent monitoring with qPCR (every
tientsofchildbearingagebeforestartingTKItherapy.Re- 1–3months)wouldbehelpfultoguidethetimingforini-
ferral to an in vitro fertilization center is recommended tiation of TKI therapy, although specific thresholds for
in coordination with the patient’s obstetrician.TKI treatmentreinitiationhavenotbeendefined.
should be stopped prior to attempting oocyte retrieval,
but the optimal timing of discontinuation is unknown.
No data areavailable to recommend how long a patient Breastfeeding
should be off therapy before oocyte retrieval, although TKI therapy can be restarted after delivery. However,
usuallyatleast1monthofftherapyisrecommended.In patients on TKI therapy should be advised not to
addition to the high incidence of disease recurrence off breastfeed,as
TKIspassintohumanbreastmilk.292–295
TKI therapy, patients should also be made aware of the BreastfeedingwithoutTKItherapymaybesafewithmo-
significant obstacles related to in vitro fertilization (eg, lecular monitoring, preferably in those patients with
lackofaccesstocentersthatperformtheprocedure,high CML who have durable DMR. It may be acceptable to
costs associated with drugs, surgical procedures, and avoid TKIs for the short period of the first 2 to 5 days
embryo/oocytestoragethatmaynotbecoveredbyin- afterlabortogivethechildcolostrum.295,296
surance,variableaccesstosurrogateprograms,theneed Closemolecularmonitoringisrecommendedforfe-
totakefamilymedicalleavefromworktoattendinvitro males who extend the treatment-free period for breast-
fertilizationappointments). feeding. If the loss of MMR after treatment cessation is
Before attempting pregnancy, patients and their confirmed, breastfeeding needs to be terminated and
partners should be counseled that no guidelines exist TKIshouldberestarted.295
JNCCN.org | Volume22 Issue1 | February2024 61

NCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024
References
1. SiegelRL,MillerKD,WagleNS,etal.Cancerstatistics,2023.CA 24. JainP,KantarjianH,PatelKP,etal.ImpactofBCR-ABLtranscripttype
CancerJClin2023;73:17–48. onoutcomeinpatientswithchronic-phaseCMLtreatedwithtyro-
2. FaderlS,TalpazM,EstrovZ,etal.Thebiologyofchronicmyeloid sinekinaseinhibitors.Blood2016;127:1269–1275.
leukemia.NEnglJMed1999;341:164–172. 25. CastagnettiF,GugliottaG,BrecciaM,etal.TheBCR-ABL1transcript
3. MeloJV.ThediversityofBCR-ABLfusionproteinsandtheirrelationship typeinfluencesresponseandoutcomeinPhiladelphiachromosome-
toleukemiaphenotype.Blood1996;88:2375–2384. positivechronicmyeloidleukemiapatientstreatedfrontlinewithimati-
4. MeloJV.BCR-ABLgenevariants.BaillieresClinHaematol1997;10:
nib.AmJHematol2017;92:797–805.
203–222. 26. PagnanoKB,MirandaEC,DelamainMT,etal.InfluenceofBCR-ABL
5. SawyersCL.Chronicmyeloidleukemia.NEnglJMed1999;340: transcripttypeonoutcomeinpatientswithchronic-phasechronicmye-
1330–1340. loidleukemiatreatedwithimatinib.ClinLymphomaMyelomaLeuk
6. RadichJP,DaiH,MaoM,etal.Geneexpressionchangesassociated
2017;17:728–733.
withprogressionandresponseinchronicmyeloidleukemia.ProcNatl 27. LeeSE,ChoiSY,KimSH,etal.BaselineBCR-ABL1transcripttypeof
AcadSciUSA2006;103:2794–2799. e13a2andlargespleensizearepredictorsofpoorlong-termoutcomes
7. JamiesonCH,AillesLE,DyllaSJ,etal.Granulocyte-macrophagepro- inchronicphasechronicmyeloidleukemiapatientswhofailedto
genitorsascandidateleukemicstemcellsinblast-crisisCML.NEnglJ achieveanearlymolecularresponseafter3monthsofimatinibtherapy.
Med2004;351:657–667. LeukLymphoma2018;59:105–113.
8. CortesJE,TalpazM,GilesF,etal.Prognosticsignificanceofcytoge- 28. ErcaliskanA,EskazanAE.TheimpactofBCR-ABL1transcripttype
neticclonalevolutioninpatientswithchronicmyelogenousleukemiaon ontyrosinekinaseinhibitorresponsesandoutcomesinpatientswith
imatinibmesylatetherapy.Blood2003;101:3794–3800. chronicmyeloidleukemia.Cancer2018;124:3806–3818.
9. O’DwyerME,MauroMJ,BlasdelC,etal.Clonalevolutionandlackof 29. PfirrmannM,EvtimovaD,SausseleS,etal.NoinfluenceofBCR-ABL1
cytogeneticresponseareadverseprognosticfactorsforhematologic transcripttypese13a2ande14a2onlong-termsurvival:resultsin1494
relapseofchronicphaseCMLpatientstreatedwithimatinibmesy- patientswithchronicmyeloidleukemiatreatedwithimatinib.JCancer
late.Blood2004;103:451–455. ResClinOncol2017;143:843–850.
10. WangW,CortesJE,LinP,etal.Clinicalandprognosticsignificanceof 30. GenthonA,NicoliniFE,HuguetF,etal.InfluenceofmajorBCR-ABL1
3q26.2andotherchromosome3abnormalitiesinCMLintheeraof transcriptsubtypeonoutcomeinpatientswithchronicmyeloidleuke-
tyrosinekinaseinhibitors.Blood2015;126:1699–1706.
miainchronicphasetreatedfrontlinewithnilotinib.Oncotarget2020;
11. WangW,TangG,CortesJE,etal.Chromosomalrearrangementin- 11:2560–2570.
volving11q23locusinchronicmyelogenousleukemia:ararephe- 31. SalmonM,WhiteHE,ZizkovaH,etal.ImpactofBCR:ABL1transcript
nomenonfrequentlyassociatedwithdiseaseprogressionandpoor typeonRT-qPCRamplificationperformanceandmolecularresponseto
prognosis.JHematolOncol2015;8:32. therapy.Leukemia2022;36:1879–1886.
12. WangW,CortesJE,TangG,etal.Riskstratificationofchromosomal 32. VermaD,KantarjianHM,JonesD,etal.Chronicmyeloidleukemia
abnormalitiesinchronicmyelogenousleukemiaintheeraoftyrosine
(CML)withP190BCR-ABL:analysisofcharacteristics,outcomes,and
kinaseinhibitortherapy.Blood2016;127:2742–2750.
prognosticsignificance.Blood2009;114:2232–2235.
13. Douet-GuilbertN,MorelF,LeCharpentierT,etal.InterphaseFISHfor
33. ArunAK,SenthamizhselviA,ManiS,etal.FrequencyofrareBCR-ABL1
follow-upofPhiladelphiachromosome-positivechronicmyeloidleuke-
miatreatment.AnticancerRes2004;24:2535–2539. f tu os li 2o 0n 1t 7ra ;3n 9s :c 2r 3ip 5t –s 2in 42c .hronicmyeloidleukemiapatients.IntJLabHema-
14. SeongDC,KantarjianHM,RoJY,etal.Hypermetaphasefluorescence 34. GongZ,MedeirosLJ,CortesJE,etal.Clinicalandprognosticsignifi-
insituhybridizationforquantitativemonitoringofPhiladelphiachromo-
canceofe1a2BCR-ABL1transcriptsubtypeinchronicmyeloidleuke-
some-positivecellsinpatientswithchronicmyelogenousleukemiadur-
ingtreatment.Blood1995;86:2343–2349. mia.BloodCancerJ2017;7:e583.
15. DewaldGW,WyattWA,JuneauAL,etal.Highlysensitivefluorescence 35. QinYZ,JiangQ,JiangH,etal.Prevalenceandoutcomesofuncommon
insituhybridizationmethodtodetectdoubleBCR/ABLfusionandmon- BCR-ABL1fusiontranscriptsinpatientswithchronicmyeloidleukaemia:
itorresponsetotherapyinchronicmyeloidleukemia.Blood1998;91:
datafromasinglecentre.BrJHaematol2018;182:693–700.
3357–3365. 36. XueM,WangQ,HuoL,etal.Clinicalcharacteristicsandprognostic
16. KantarjianHM,TalpazM,CortesJ,etal.Quantitativepolymerasechain
significanceofchronicmyeloidleukemiawithrareBCR-ABL1tran-
reactionmonitoringofBCR-ABLduringtherapywithimatinibmesylate scripts.LeukLymphoma2019;60:3051–3057.
(STI571;gleevec)inchronic-phasechronicmyelogenousleukemia.Clin 37. Adnan-AwadS,KimD,HohtariH,etal.Characterizationofp190-Bcr-Abl
CancerRes2003;9:160–166. chronicmyeloidleukemiarevealsspecificsignalingpathwaysand
17. HughesT,DeiningerMW,HochhausA,etal.MonitoringCMLpatients therapeutictargets.Leukemia2021;35:1964–1975.
respondingtotreatmentwithtyrosinekinaseinhibitors:reviewandrec- 38. AbdelmagidMG,LitzowMR,McCulloughKB,etal.ChronicphaseCML
ommendationsforharmonizingcurrentmethodologyfordetecting withsoleP190(e1a2)BCR:ABL1:long-termoutcomeamongten
BCR-ABLtranscriptsandkinasedomainmutationsandforexpressing consecutivecases.BloodCancerJ2022;12:103.
results.Blood2006;108:28–37.
39. VerstovsekS,LinH,KantarjianH,etal.Neutrophilic-chronicmyeloid
18. BiernauxC,LoosM,SelsA,etal.DetectionofmajorBCR-ABLgeneex- leukemia:lowlevelsofp230BCR/ABLmRNAandundetectable
pressionataverylowlevelinbloodcellsofsomehealthyindividuals.
BCR/ABLproteinmaypredictanindolentcourse.Cancer2002;94:
Blood1995;86:3118–3122.
2416–2425.
19. BoseS,DeiningerMW,Gora-TyborJ,etal.Thepresenceoftypicaland
40. LangabeerSE,McCarronSL,KellyJ,etal.Chronicmyeloidleukemia
atypicalBCR-ABLfusiongenesinleukocytesofnormalindividuals:bio-
logicsignificanceandimplicationsfortheassessmentofminimalresid- withe19a2BCR-ABL1transcriptsandmarkedthrombocytosis:therole
ualdisease.Blood1998;92:3362–3367. ofmolecularmonitoring.CaseRepHematol2012;2012:458716.
41. CrampeM,HaslamK,KellyJ,etal.Characterizationofanovelvariant
20. BaccaraniM,CastagnettiF,GugliottaG,etal.Theproportionofdiffer-
BCR-ABL1fusiontranscriptinapatientwithchronicmyeloidleukemia:
entBCR-ABL1transcripttypesinchronicmyeloidleukemia.Aninterna-
tionaloverview.Leukemia2019;33:1173–1183. implicationsformolecularmonitoring.HematolOncolStemCellTher
2017;10:85–88.
21. GhalesardiOK,KhosraviA,AziziE,etal.Theprognosticimportanceof
BCR-ABLtranscriptsinchronicmyeloidleukemia:asystematicreview 42. LangabeerSE.StandardizedmolecularmonitoringforvariantBCR-ABL1
andmeta-analysis.LeukRes2021;101:106512. transcriptsinchronicmyeloidleukemia.ArchPatholLabMed2015;
139:969.
22. LucasCM,HarrisRJ,GiannoudisA,etal.Chronicmyeloidleukemiapa-
tientswiththee13a2BCR-ABLfusiontranscripthaveinferiorresponses 43. ShanmuganathanN,HughesTP.MolecularmonitoringinCML:how
toimatinibcomparedtopatientswiththee14a2transcript.Haemato- deep?Howoften?Howshoulditinfluencetherapy?HematologyAm
logica2009;94:1362–1367. SocHematolEducProgram2018;2018:168–176.
23. HanfsteinB,LausekerM,HehlmannR,etal.Distinctcharacteristicsof 44. BurmeisterT,ReinhardtR.AmultiplexPCRforimproveddetection
e13a2versuse14a2BCR-ABL1drivenchronicmyeloidleukemiaunder oftypicalandatypicalBCR-ABLfusiontranscripts.LeukRes2008;32:
first-linetherapywithimatinib.Haematologica2014;99:1441–1447. 579–585.
62 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024

ChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®
45. BennourA,OuahchiI,MoezM,etal.ComprehensiveanalysisofBCR/ 64. NiH,SunX,XuY,etal.Clinicalimplicationsofclonalchromosomalab-
ABLvariantsinchronicmyeloidleukemiapatientsusingmultiplexRT- normalitiesinPhiladelphianegativecellsinCMLpatientsaftertreated
PCR.ClinLab2012;58:433–439. withtyrosinekinaseinhibitors.CancerGenet2019;238:44–49.
46. MirR,AhmadI,JavidJ,etal.SimplemultiplexRT-PCRforidentifying 65. ShengG,XueM,WangQ,etal.Occurrenceofchromosomalabnor-
commonfusionBCR-ABLtranscripttypesandevaluationofmolecular malitiesinPhiladelphiachromosome-negativemetaphasesinpatients
responseofthea2b2anda2b3transcriptstoImatinibresistancein withchronic-phasechronicmyeloidleukemiaundergoingTKItreat-
northIndianchronicmyeloidleukemiapatients.IndianJCancer2015; ments.LeukLymphoma2019;60:3503–3511.
52:314–318. 66. IssaGC,KantarjianHM,GonzalezGN,etal.Clonalchromosomal
47. PaganiIS,DangP,SaundersVA,etal.ClinicalutilityofgenomicDNA abnormalitiesappearinginPhiladelphiachromosome-negative
Q-PCRforthemonitoringofapatientwithatypicale19a2BCR-ABL1 metaphasesduringCMLtreatment.Blood2017;130:2084–2091.
transcriptsinchronicmyeloidleukemia.LeukLymphoma2020;61: 67. KarimataK,MasukoM,UshikiT,etal.Myelodysplasticsyndromewith
2527–2529. Phnegativemonosomy7chromosomefollowingtransientbonemarrow
48. PetitiJ,LoIaconoM,DraganiM,etal.Novelmultiplexdropletdigital dysplasiaduringimatinibtreatmentforchronicmyeloidleukemia.Intern
PCRassaystomonitorminimalresidualdiseaseinchronicmyeloidleu- Med2011;50:481–485.
kemiapatientsshowingatypicalBCR-ABL1transcripts.JClinMed 68. NavarroJT,FeliuE,GrauJ,etal.Monosomy7withseveremyelodys-
2020;9:1457. plasiadevelopingduringimatinibtreatmentofPhiladelphia-positive
49. VermaD,KantarjianH,ShanJ,etal.Survivaloutcomesforclonalevolu- chronicmyeloidleukemia:twocaseswithadifferentoutcome.AmJ
tioninchronicmyeloidleukemiapatientsonsecondgenerationtyrosine
Hematol2007;82:849–851.
kinaseinhibitortherapy.Cancer2010;116:2673–2681. 69. BidetA,DulucqS,SmolT,etal.Poorprognosisofchromosome7
50. FabariusA,KalmantiL,DietzCT,etal.Impactofunbalancedminor clonalaberrationsinPhiladelphia-negativemetaphasesandrelevance
routeversusmajorroutekaryotypesatdiagnosisonprognosisofCML. ofpotentialunderlyingmyelodysplasticfeaturesinchronicmyeloidleu-
AnnHematol2015;94:2015–2024. kemia.Haematologica2019;104:1150–1155.
51. FabariusA,LeitnerA,HochhausA,etal.Impactofadditionalcytoge- 70. SokalJE,CoxEB,BaccaraniM,etal.Prognosticdiscriminationin
neticaberrationsatdiagnosisonprognosisofCML:long-termobserva-
“good-risk”chronicgranulocyticleukemia.Blood1984;63:789–799.
tionof1151patientsfromtherandomizedCMLStudyIV.Blood2011; 71. HasfordJ,PfirrmannM,HehlmannR,etal.Anewprognosticscorefor
118:6760–6768. survivalofpatientswithchronicmyeloidleukemiatreatedwithinter-
52. HehlmannR,VoskanyanA,LausekerM,etal.High-riskadditionalchro-
feronalfa.JNatlCancerInst1998;90:850–858.
mosomalabnormalitiesatlowblastcountsheralddeathbyCML.Leuke- 72. PfirrmannM,BaccaraniM,SausseleS,etal.Prognosisoflong-term
mia2020;34:2074–2086. survivalconsideringdisease-specificdeathinpatientswithchronic
53. AlhuraijiA,KantarjianH,BodduP,etal.Prognosticsignificanceofaddi- myeloidleukemia.Leukemia2016;30:48–56.
tionalchromosomalabnormalitiesatthetimeofdiagnosisinpatients 73. GrossmannV,KohlmannA,ZengerM,etal.Adeep-sequencingstudy
withchronicmyeloidleukemiatreatedwithfrontlinetyrosinekinasein- ofchronicmyeloidleukemiapatientsinblastcrisis(BC-CML)detects
hibitors.AmJHematol2018;93:84–90. mutationsin76.9%ofcases.Leukemia2011;25:557–560.
54. BummT,Mu€llerC,Al-AliHK,etal.Emergenceofclonalcytogeneticab- 74. MakishimaH,JankowskaAM,McDevittMA,etal.CBL,CBLB,TET2,
normalitiesinPh-cellsinsomeCMLpatientsincytogeneticremission ASXL1,andIDH1/2mutationsandadditionalchromosomalaberrations
toimatinibbutrestorationofpolyclonalhematopoiesisinthemajority. constitutemoleculareventsinchronicmyelogenousleukemia.Blood
Blood2003;101:1941–1949. 2011;117:e198–206.
55. FeldmanE,NajfeldV,SchusterM,etal.TheemergenceofPh-,trisomy 75. KimT,TyndelMS,ZhangZ,etal.ExomesequencingrevealsDNMT3A
-81cellsinpatientswithchronicmyeloidleukemiatreatedwithimatinib andASXL1variantsassociatewithprogressionofchronicmyeloidleuke-
mesylate.ExpHematol2003;31:702–707. miaaftertyrosinekinaseinhibitortherapy.LeukRes2017;59:142–148.
56. MedinaJ,KantarjianH,TalpazM,etal.Chromosomalabnormalitiesin 76. KimT,TyndelMS,KimHJ,etal.Spectrumofsomaticmutationdynam-
Philadelphiachromosome-negativemetaphasesappearingduringimati- icsinchronicmyeloidleukemiafollowingtyrosinekinaseinhibitorther-
nibmesylatetherapyinpatientswithPhiladelphiachromosome-positive apy.Blood2017;129:38–47.
chronicmyelogenousleukemiainchronicphase.Cancer2003;98: 77. MologniL,PiazzaR,KhandelwalP,etal.Somaticmutationsidentified
1905–1911. atdiagnosisbyexomesequencingcanpredictresponsetoimatinibin
57. TerreC,EclacheV,RousselotP,etal.Reportof34patientswithclonal chronicphasechronicmyeloidleukemia(CML)patients.AmJHematol
chromosomalabnormalitiesinPhiladelphia-negativecellsduringimati-
2017;92:E623–625.
nibtreatmentofPhiladelphia-positivechronicmyeloidleukemia.Leuke- 78. TogasakiE,TakedaJ,YoshidaK,etal.Frequentsomaticmutationsin
mia2004;18:1340–1346. epigeneticregulatorsinnewlydiagnosedchronicmyeloidleukemia.
58. DeiningerMW,CortesJ,PaquetteR,etal.Theprognosisforpatients BloodCancerJ2017;7:e559.
withchronicmyeloidleukemiawhohaveclonalcytogeneticabnor- 79. BranfordS,WangP,YeungDT,etal.Integrativegenomicanalysisre-
malitiesinPhiladelphiachromosome-negativecells.Cancer2007; vealscancer-associatedmutationsatdiagnosisofCMLinpatientswith
110:1509–1519. high-riskdisease.Blood2018;132:948–961.
€
59. JabbourE,KantarjianHM,AbruzzoLV,etal.Chromosomalabnormali- 80. ErbilginY,EskazanAE,HatirnazNgO,etal.DeepsequencingofBCR-
tiesinPhiladelphiachromosomenegativemetaphasesappearingdur- ABL1kinasedomainmutationsinchronicmyeloidleukemiapatients
ingimatinibmesylatetherapyinpatientswithnewlydiagnosedchronic withresistancetotyrosinekinaseinhibitors.LeukLymphoma2019;60:
myeloidleukemiainchronicphase.Blood2007;110:2991–2995. 200–207.
60. VignettiM,FaziP,CiminoG,etal.Imatinibplussteroidsinducescom- 81. NteliopoulosG,BazeosA,ClaudianiS,etal.Somaticvariantsinepige-
pleteremissionsandprolongedsurvivalinelderlyPhiladelphiachromo- neticmodifierscanpredictfailureofresponsetoimatinibbutnotto
some-positivepatientswithacutelymphoblasticleukemiawithout second-generationtyrosinekinaseinhibitors.Haematologica2019;104:
additionalchemotherapy:resultsoftheGruppoItalianoMalattieEmato- 2400–2409.
logichedell’Adulto(GIMEMA)LAL0201-Bprotocol.Blood2007;109: 82. AdnanAwadS,KankainenM,OjalaT,etal.Mutationaccumulationin
3676–3678. cancergenesrelatestononoptimaloutcomeinchronicmyeloidleuke-
61. FabariusA,HaferlachC,Mu€llerMC,etal.Dynamicsofcytogenetic mia.BloodAdv2020;4:546–559.
aberrationsinPhiladelphiachromosomepositiveandnegativehemato- 83. WuW,XuN,ZhouX,etal.Integrativegenomicanalysisrevealscancer-
poiesisduringdasatinibtherapyofchronicmyeloidleukemiapatients associatedgenemutationsinchronicmyeloidleukemiapatientswithre-
afterimatinibfailure.Haematologica2007;92:834–837. sistanceorintolerancetotyrosinekinaseinhibitor.OncoTargetsTher
62. BaldazziC,LuattiS,MarzocchiG,etal.Emergenceofclonalchromo-
2020;13:8581–8591.
somalabnormalitiesinPhiladelphianegativehematopoiesisinchronic 84. AdnanAwadS,DufvaO,IanevskiA,etal.RUNX1mutationsin
myeloidleukemiapatientstreatedwithnilotinibafterfailureofimatinib blast-phasechronicmyeloidleukemiaassociatewithdistinctpheno-
therapy.LeukRes2009;33:e218–220. types,transcriptionalprofiles,anddrugresponses.Leukemia2021;
63. WangH,JinJ,WangY,etal.Clonalchromosomalabnormalitiesin
35:1087–1099.
Philadelphia-negativecellsinchronicmyeloidleukemiapatients 85. OchiY,YoshidaK,HuangYJ,etal.Clonalevolutionandclinicalimplica-
treatedwithnilotinibusedinfirst-linetherapy.AnnHematol2013; tionsofgeneticabnormalitiesinblastictransformationofchronicmye-
92:1625–1632. loidleukaemia.NatCommun2021;12:2833.
JNCCN.org | Volume22 Issue1 | February2024 63

NCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024
86. BidikianA,KantarjianH,JabbourE,etal.PrognosticimpactofASXL1 107. PorkkaK,KhouryHJ,PaquetteRL,etal.Dasatinib100mgoncedaily
mutationsinchronicphasechronicmyeloidleukemia.BloodCancerJ minimizestheoccurrenceofpleuraleffusioninpatientswithchronicmy-
2022;12:144. eloidleukemiainchronicphaseandefficacyisunaffectedinpatients
87. Scho€nfeldL,RinkeJ,HinzeA,etal.ASXL1mutationspredictinferior whodeveloppleuraleffusion.Cancer2010;116:377–386.
molecularresponsetonilotinibtreatmentinchronicmyeloidleukemia. 108. MontaniD,BergotE,Gu€ntherS,etal.Pulmonaryarterialhypertension
Leukemia2022;36:2242–2249. inpatientstreatedbydasatinib.Circulation2012;125:2128–2137.
88. AdnanAwadS,Bru€ckO,ShanmuganathanN,etal.Epigeneticmodifier 109. OrlandiEM,RoccaB,PazzanoAS,etal.Reversiblepulmonaryarterial
genemutationsinchronicmyeloidleukemia(CML)atdiagnosisareas- hypertensionlikelyrelatedtolong-term,low-dosedasatinibtreatment
sociatedwithriskofrelapseupontreatmentdiscontinuation.Blood forchronicmyeloidleukaemia.LeukRes2012;36:e4–6.
CancerJ2022;12:69. 110. CirmiS,ElAbdA,LetinierL,etal.Cardiovasculartoxicityoftyrosine
89. KizilorsA,Crisa(cid:2)E,LeaN,etal.Effectoflow-levelBCR-ABL1kinase kinaseinhibitorsusedinchronicmyeloidleukemia:ananalysisofthe
domainmutationsidentifiedbynext-generationsequencingin FDAAdverseEventReportingSystemDatabase(FAERS).Cancers
patientswithchronicmyeloidleukaemia:apopulation-basedstudy. (Basel)2020;12:826.
LancetHaematol2019;6:e276–284.
111. EfficaceF,BaccaraniM,BrecciaM,etal.Chronicfatigueisthemostim-
90. SoveriniS,BavaroL,DeBenedittisC,etal.Prospectiveassessmentof portantfactorlimitinghealth-relatedqualityoflifeofchronicmyeloid
NGS-detectablemutationsinCMLpatientswithnonoptimalresponse: leukemiapatientstreatedwithimatinib.Leukemia2013;27:1511–1519.
theNEXT-in-CMLstudy.Blood2020;135:534–541.
112. BermanE,NicolaidesM,MakiRG,etal.Alteredboneandmineral
91. SchmidtM,RinkeJ,Scha€ferV,etal.Molecular-definedclonalevolution metabolisminpatientsreceivingimatinibmesylate.NEnglJMed
inpatientswithchronicmyeloidleukemiaindependentoftheBCR-ABL 2006;354:2006–2013.
status.Leukemia2014;28:2292–2299.
113. BermanE,GirotraM,ChengC,etal.Effectoflongtermimatinibon
92. HochhausA,LarsonRA,GuilhotF,etal.Long-termoutcomesofimati- boneinadultswithchronicmyelogenousleukemiaandgastrointestinal
nibtreatmentofchronicmyeloidleukemia.NEnglJMed2017;376: stromaltumors.LeukRes2013;37:790–794.
917–927.
114. TsaoAS,KantarjianHM,CortesJE,etal.Imatinibmesylatecauses
93. CortesJE,SaglioG,KantarjianHM,etal.Final5-yearstudyresults hypopigmentationintheskin.Cancer2003;98:2483–2487.
ofDASISION:thedasatinibversusimatinibstudyintreatment-naive
115. AleemA.Hypopigmentationoftheskinduetoimatinibmesylatein
chronicmyeloidleukemiapatientstrial.JClinOncol2016;34:
2333–2340. p That ei ren 2t 0s 0w 9;i 2th :3c 5h 8r –o 3n 6ic 1.myeloidleukemia.HematolOncolStemCell
94. CortesJE,Gambacorti-PasseriniC,DeiningerMW,etal.Bosutinibversus
116. SakuraiM,KikuchiT,KariganeD,etal.Renaldysfunctionandanemia
imatinibfornewlydiagnosedchronicmyeloidleukemia:resultsfromthe
randomizedBFOREtrial.JClinOncol2018;36:231–237. a ms ys eo lc oia gt ee nd ow usith leulo kn eg m-t ie a.rm Intim Ja Hti en mib at tr oe la 2tm 01e 9n ;1t 0in 9:p 2a 9t 2ie –n 2t 9s 8w .ithchronic
95. Bru€mmendorfTH,CortesJE,MilojkovicD,etal.Bosutinibversusimati-
nibfornewlydiagnosedchronicphasechronicmyeloidleukemia:final 117. ReinholdU,HennigE,LeibleinS,etal.FISHforBCR-ABLoninter-
resultsfromtheBFOREtrial.Leukemia2022;36:1825–1833. phasesofperipheralbloodneutrophilsbutnotofunselectedwhitecells
correlateswithbonemarrowcytogeneticsinCMLpatientstreatedwith
96. KantarjianHM,HughesTP,LarsonRA,etal.Long-termoutcomeswith imatinib.Leukemia2003;17:1925–1929.
frontlinenilotinibversusimatinibinnewlydiagnosedchronicmyeloid 118. FugazzaG,MiglinoM,BruzzoneR,etal.Cytogeneticandfluorescence
leukemiainchronicphase:ENESTnd10-yearanalysis.Leukemia2021;
35:440–453.
insituhybridizationmonitoringinPh1chronicmyeloidleukemiapa-
tientstreatedwithimatinibmesylate.JExpClinCancerRes2004;23:
97. GemelliM,ElliEM,ElenaC,etal.Useofgenericimatinibasfirst-line 295–299.
treatmentinpatientswithchronicmyeloidleukemia(CML):theGIMS
(GlivectoImatinibSwitch)study.BloodRes2020;55:139–145. 119. LandstromAP,KetterlingRP,KnudsonRA,etal.Utilityofperipheral
blooddualcolor,doublefusionfluorescentinsituhybridizationfor
98. ScalzulliE,ColafigliG,LatagliataR,etal.Switchfrombrandedto
BCR/ABLfusiontoassesscytogeneticremissionstatusinchronicmye-
genericimatinib:impactonmolecularresponsesandsafetyin loidleukemia.LeukLymphoma2006;47:2055–2061.
chronic-phasechronicmyeloidleukemiapatients.AnnHematol
2020;99:2773–2777. 120. TestoniN,MarzocchiG,LuattiS,etal.Chronicmyeloidleukemia:apro-
99. E efr fic¸a cl aıs c¸k yan anA d, sS ae fy eh ta yn oE fr gd eo ng(cid:3) ea rn icD im,E as t¸k ina iz ban inA CE M.C Lu arr ne dnt the evid ime pnc ae cto on fthe csp hre oc mtiv oe soc mom ep ba ar nis do in ngof ai nn at le yr sp isha fos re tfl hu eo dre es fic ne itn ioce ni on fs ci otu mh py lb er teidi cz ya tt oio gn e-and
genericsonhealthcarecosts.BloodAdv2021;5:3344–3353. n 4e 9t 3ic 9–r 4e 9sp 4o 3.nse:astudyoftheGIMEMACMLWP.Blood2009;114:
100. KantarjianHM,PaulS,ThakkarJ,etal.Theinfluenceofdrugprices,
121. LimaL,Bernal-MizrachiL,SaxeD,etal.Peripheralbloodmonitoringof
newavailabilityofinexpensivegenericimatinib,newapprovals,and
chronicmyeloidleukemiaduringtreatmentwithimatinib,second-line
p ino ts ht- em Ua Srk Ae .ti Ln ag ncre es te Ha arc eh mo an tot lh 2e 0t 2r 2e ;a 9t :m e8e 5n 4t –o 8f 6c 1h .ronicmyeloidleukaemia agents,andbeyond.Cancer2011;117:1245–1252.
122. HughesTP,HochhausA,BranfordS,etal.Long-termprognosticsignifi-
101. BaccaraniM,DrukerBJ,BranfordS,etal.Long-termresponsetoimati-
canceofearlymolecularresponsetoimatinibinnewlydiagnosed
nibisnotaffectedbytheinitialdoseinpatientswithPhiladelphiachro-
mosome-positivechronicmyeloidleukemiainchronicphase:final c izh er don Si tc um dyye ol fo Ii nd tele rfu ek re om ni aa n: dan Sa Tn I5a 7ly 1si (s IRf Ir So )m .Bt lh oe odIn 2te 0r 1n 0a ;t 1io 1n 6a :3l 7R 5a 8n –d 3o 7m 65-
.
updatefromtheTyrosineKinaseInhibitorOptimizationandSelectivity
(TOPS)study.IntJHematol2014;99:616–624. 123. AkardLP,CortesJE,AlbitarM,etal.Correlationsbetweencytogenetic
andmolecularmonitoringamongpatientswithnewlydiagnosed
102. DeiningerMW,KopeckyKJ,RadichJP,etal.Imatinib800mgdailyin-
chronicmyeloidleukemiainchronicphase:posthocanalysesoftheRa-
ducesdeepermolecularresponsesthanimatinib400mgdaily:results
tionaleandInsightforGleevecHigh-DoseTherapystudy.ArchPathol
ofSWOGS0325,anintergrouprandomizedPHASEIItrialinnewlydi-
LabMed2014;138:1186–1192.
agnosedchronicphasechronicmyeloidleukaemia.BrJHaematol
2014;164:223–232. 124. BranfordS,CrossNC,HochhausA,etal.Rationalefortherecommen-
dationsforharmonizingcurrentmethodologyfordetectingBCR-ABL
103. HehlmannR,LausekerM,SausseleS,etal.Assessmentofimatinibas
first-linetreatmentofchronicmyeloidleukemia:10-yearsurvivalresults transcriptsinpatientswithchronicmyeloidleukaemia.Leukemia2006;
oftherandomizedCMLstudyIVandimpactofnon-CMLdeterminants.
20:1925–1930.
Leukemia2017;31:2398–2406. 125. CrossNC.Standardisationofmolecularmonitoringforchronicmyeloid
104. HoffmannVS,HasfordJ,DeiningerMW,etal.Systematicreviewand
leukaemia.BestPractResClinHaematol2009;22:355–365.
meta-analysisofstandard-doseimatinibvs.high-doseimatinibandsec- 126. CrossNC,WhiteHE,Mu€llerMC,etal.Standardizeddefinitionsof
ondgenerationtyrosinekinaseinhibitorsforchronicmyeloidleukemia. molecularresponseinchronicmyeloidleukemia.Leukemia2012;26:
JCancerResClinOncol2017;143:1311–1318. 2172–2175.
105. Quinta(cid:4)s-CardamaA,HanX,KantarjianHM,etal.Tyrosinekinase 127. BranfordS,FletcherL,CrossNC,etal.Desirableperformancecharac-
inhibitor-inducedplateletdysfunctioninpatientswithchronicmyeloid teristicsforBCR-ABLmeasurementonaninternationalreportingscale
leukemia.Blood2009;114:261–263. toallowconsistentinterpretationofindividualpatientresponseand
106. HughesTP,LaneuvilleP,RousselotP,etal.Incidence,outcomes,and comparisonofresponseratesbetweenclinicaltrials.Blood2008;112:
riskfactorsofpleuraleffusioninpatientsreceivingdasatinibtherapyfor
3330–3338.
Philadelphiachromosome-positiveleukemia.Haematologica2019;104: 128. Gue(cid:4)rinA,ChenL,DeaK,etal.Associationbetweenregularmolecular
93–101. monitoringandtyrosinekinaseinhibitortherapyadherenceinchronic
64 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024

ChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®
myelogenousleukemiainthechronicphase.CurrMedResOpin2014; 149. MarinD,GoldmanJM,OlavarriaE,etal.Transientbenefitonlyfromin-
30:1345–1352. creasingtheimatinibdoseinCMLpatientswhodonotachievecom-
129. HanfsteinB,Mu€llerMC,HehlmannR,etal.Earlymolecularandcyto- pletecytogeneticremissionsonconventionaldoses.Blood2003;102:
geneticresponseispredictiveforlong-termprogression-freeand 2702–2703;authorreply2703–2704.
overallsurvivalinchronicmyeloidleukemia(CML).Leukemia2012; 150. JabbourE,KantarjianHM,JonesD,etal.Imatinibmesylatedoseesca-
26:2096–2102. lationisassociatedwithdurableresponsesinpatientswithchronicmye-
130. MarinD,IbrahimAR,LucasC,etal.AssessmentofBCR-ABL1transcript loidleukemiaaftercytogeneticfailureonstandard-doseimatinib
levelsat3monthsistheonlyrequirementforpredictingoutcomefor therapy.Blood2009;113:2154–2160.
patientswithchronicmyeloidleukemiatreatedwithtyrosinekinasein- 151. KantarjianHM,LarsonRA,GuilhotF,etal.Efficacyofimatinibdosees-
hibitors.JClinOncol2012;30:232–238.
calationinpatientswithchronicmyeloidleukemiainchronicphase.
131. NeelakantanP,GerrardG,LucasC,etal.CombiningBCR-ABL1tran- Cancer2009;115:551–560.
scriptlevelsat3and6monthsinchronicmyeloidleukemia:implications 152. YeungDT,OsbornMP,WhiteDL,etal.TIDEL-II:first-lineuseofimati-
forearlyinterventionstrategies.Blood2013;121:2739–2742.
nibinCMLwithearlyswitchtonilotinibforfailuretoachievetime-
132. NazhaA,KantarjianHM,JainP,etal.Assessmentat6monthsmaybe dependentmoleculartargets.Blood2015;125:915–923.
warrantedforpatientswithchronicmyeloidleukemiawithnomajorcy- 153. CortesJE,DeSouzaCA,AyalaM,etal.Switchingtonilotinibversusim-
togeneticresponseat3months.Haematologica2013;98:1686–1688.
atinibdoseescalationinpatientswithchronicmyeloidleukaemiain
133. BranfordS,YeungDT,ParkerWT,etal.Prognosisforpatientswith chronicphasewithsuboptimalresponsetoimatinib(LASOR):arando-
CMLand.10%BCR-ABL1after3monthsofimatinibdependsonthe mised,open-labeltrial.LancetHaematol2016;3:e581–591.
rateofBCR-ABL1decline.Blood2014;124:511–518.
154. CortesJE,JiangQ,WangJ,etal.Dasatinibvs.imatinibinpatientswith
134. HanfsteinB,ShlyakhtoV,LausekerM,etal.VelocityofearlyBCR-ABL chronicmyeloidleukemiainchronicphase(CML-CP)whohavenot
transcripteliminationasanoptimizedpredictorofoutcomeinchronic achievedanoptimalresponseto3monthsofimatinibtherapy:the
myeloidleukemia(CML)patientsinchronicphaseontreatmentwithim- DASCERNrandomizedstudy.Leukemia2020;34:2064–2073.
atinib.Leukemia2014;28:1988–1992.
155. ShahNP,RousselotP,SchifferC,etal.Dasatinibinimatinib-resistantor
135. IriyamaN,FujisawaS,YoshidaC,etal.ShorterhalvingtimeofBCR- -intolerantchronic-phase,chronicmyeloidleukemiapatients:7-yearfol-
ABL1transcriptsisanovelpredictorforachievementofmolecularre- low-upofstudyCA180-034.AmJHematol2016;91:869–874.
sponsesinnewlydiagnosedchronic-phasechronicmyeloidleukemia
treatedwithdasatinib:resultsoftheD-firststudyofKantoCMLstudy 156. GilesFJ,leCoutrePD,Pinilla-IbarzJ,etal.Nilotinibinimatinib-resistant
group.AmJHematol2015;90:282–287. orimatinib-intolerantpatientswithchronicmyeloidleukemiainchronic
136. rH eo cc eh ivh ina gus imA, atO in’ iB bri fe on rS thG e, fiG rsu ti -lh lino etF tr, ee at tmal e. nS tix o-y fe ca hr rofo nl il cow m- yu ep loo idfp lea uti ke en -ts p 27h :a 1s 0e 7: –4 18 1- 2m .onthfollow-upresultsofaphaseIIstudy.Leukemia2013;
mia.Leukemia2009;23:1054–1061. 157. Gambacorti-PasseriniC,CortesJE,LiptonJH,etal.Safetyandefficacy
137. JabbourE,KantarjianHM,O’BrienS,etal.Theachievementofanearly o of vese rc ao fin vd e- -li yn ee arb po esu rit oin di :b fif no ar lc rh er so un lti sc op fh aas pe hc ah sero In /Iic Ism tuy de ylo .i Hd al ee muk ae tm oloia
gica
completecytogeneticresponseisamajordeterminantforoutcomein 2018;103:1298–1307.
patientswithearlychronicphasechronicmyeloidleukemiatreatedwith
tyrosinekinaseinhibitors.Blood2011;118:4541–4546;quiz4759. 158. CortesJE,KhouryHJ,KantarjianHM,etal.Long-termbosutinibfor
138. DrukerBJ,GuilhotF,O’BrienSG,etal.Five-yearfollow-upofpatients chronicphasechronicmyeloidleukemiaafterfailureofimatinibplusda-
receivingimatinibforchronicmyeloidleukemia.NEnglJMed2006;
satiniband/ornilotinib.AmJHematol2016;91:1206–1214.
355:2408–2417. 159. HochhausA,Gambacorti-PasseriniC,AbboudC,etal.Bosutinibfor
139. PressRD,GalderisiC,YangR,etal.Ahalf-logincreaseinBCR-ABL pretreatedpatientswithchronicphasechronicmyeloidleukemia:
RNApredictsahigherriskofrelapseinpatientswithchronicmyeloid primaryresultsofthephase4BYONDstudy.Leukemia2020;34:
leukemiawithanimatinib-inducedcompletecytogeneticresponse.Clin
2125–2137.
CancerRes2007;13:6136–6143. 160. CortesJE,KimDW,Pinilla-IbarzJ,etal.Ponatinibefficacyandsafetyin
140. deLavalladeH,ApperleyJF,KhorashadJS,etal.Imatinibfornewly
Philadelphiachromosome-positiveleukemia:final5-yearresultsofthe
diagnosedpatientswithchronicmyeloidleukemia:incidenceofsus-
phase2PACEtrial.Blood2018;132:393–404.
tainedresponsesinanintention-to-treatanalysis.JClinOncol2008; 161. CortesJE,ApperleyJ,LomaiaE,etal.Ponatinibdose-rangingstudyin
26:3358–3363. chronic-phasechronicmyeloidleukemia:arandomized,open-label
141. MarinD,MilojkovicD,OlavarriaE,etal.EuropeanLeukemiaNetcriteria phase2clinicaltrial.Blood2021;138:2042–2050.
forfailureorsuboptimalresponsereliablyidentifypatientswithCMLin 162. HughesTP,MauroMJ,CortesJE,etal.Asciminibinchronicmyeloid
earlychronicphasetreatedwithimatinibwhoseeventualoutcomeis leukemiaafterABLkinaseinhibitorfailure.NEnglJMed2019;381:
poor.Blood2008;112:4437–4444. 2315–2326.
142. JabbourE,KantarjianHM,O’BrienS,etal.Front-linetherapywithsec- 163. Re(cid:4)aD,MauroMJ,BoquimpaniC,etal.Aphase3,open-label,ran-
ond-generationtyrosinekinaseinhibitorsinpatientswithearlychronic domizedstudyofasciminib,aSTAMPinhibitor,vsbosutinibinCML
phasechronicmyeloidleukemia:whatistheoptimalresponse?JClin after2ormorepriorTKIs.Blood2021;138:2031–2041.
Oncol2011;29:4260–4265.
164. HochhausA,Re(cid:4)aD,BoquimpaniC,etal.Asciminibvsbosutinibin
143. HehlmannR,Mu€llerMC,LausekerM,etal.Deepmolecularre- chronic-phasechronicmyeloidleukemiapreviouslytreatedwithatleast
sponseisreachedbythemajorityofpatientstreatedwithimatinib, twotyrosinekinaseinhibitors:longer-termfollow-upofASCEMBL.
predictssurvival,andisachievedmorequicklybyoptimizedhigh- Leukemia2023;37:617–626.
doseimatinib:resultsfromtherandomizedCML-studyIV.JClin
Oncol2014;32:415–423. 165. DorerDJ,KnickerbockerRK,BaccaraniM,etal.Impactofdoseintensity
ofponatinibonselectedadverseevents:multivariateanalysesfroma
144. SausseleS,HehlmannR,FabariusA,etal.Definingtherapygoalsfor pooledpopulationofclinicaltrialpatients.LeukRes2016;48:84–91.
majormolecularremissioninchronicmyeloidleukemia:resultsofthe
randomizedCMLStudyIV.Leukemia2018;32:1222–1228. 166. JainP,KantarjianHM,BodduPC,etal.Analysisofcardiovascularand
145. CervantesF,Lo(cid:4)pez-GarridoP,MonteroMI,etal.Earlyinterventiondur- a frr ote nr ti lo int ehr To Km Isb .o Bti loc oa ddv Ae drs ve 2e 0v 1e 9n ;3ts :8in 51c –h 8ro 61n .ic-phaseCMLpatientsafter
ingimatinibtherapyinpatientswithnewlydiagnosedchronic-phase
chronicmyeloidleukemia:astudyoftheSpanishPETHEMAgroup. 167. CaocciG,MulasO,AbruzzeseE,etal.Arterialocclusiveeventsin
Haematologica2010;95:1317–1324. chronicmyeloidleukemiapatientstreatedwithponatinibinthereal-life
practicearepredictedbytheSystematicCoronaryRiskEvaluation
146. KantarjianHM,CortesJ.Considerationsinthemanagementof (SCORE)chart.HematolOncol2019;37:296–302.
patientswithPhiladelphiachromosome-positivechronicmyeloid
leukemiareceivingtyrosinekinaseinhibitortherapy.JClinOncol 168. CasavecchiaG,GalderisiM,NovoG,etal.Earlydiagnosis,clinicalman-
2011;29:1512–1516. agement,andfollow-upofcardiovasculareventswithponatinib.Heart
147. HochhausA,BaccaraniM,SilverRT,etal.EuropeanLeukemiaNet2020
FailRev2020;25:447–456.
recommendationsfortreatingchronicmyeloidleukemia.Leukemia 169. CortesJE,LiptonJH,ReaD,etal.Phase2studyofsubcutaneousoma-
2020;34:966–984. cetaxinemepesuccinateafterTKIfailureinpatientswithchronic-phase
148. KantarjianHM,TalpazM,O’BrienS,etal.Doseescalationofimatinib CMLwithT315Imutation.Blood2012;120:2573–2580.
mesylatecanovercomeresistancetostandard-dosetherapyinpatients 170. CortesJE,DigumartiR,ParikhPM,etal.Phase2studyofsubcutaneous
withchronicmyelogenousleukemia.Blood2003;101:473–475. omacetaxinemepesuccinateforchronic-phasechronicmyeloidleukemia
JNCCN.org | Volume22 Issue1 | February2024 65

NCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024
patientsresistanttoorintolerantoftyrosinekinaseinhibitors.AmJHem- 193. WhiteDL,SaundersVA,DangP,etal.OCT-1-mediatedinfluxisakey
atol2013;88:350–354. determinantoftheintracellularuptakeofimatinibbutnotnilotinib
171. GargRJ,KantarjianHM,O’BrienS,etal.Theuseofnilotinibordasati- (AMN107):reducedOCT-1activityisthecauseoflowinvitrosensitivity
nibafterfailureto2priortyrosinekinaseinhibitors:long-termfollow-up.
toimatinib.Blood2006;108:697–704.
Blood2009;114:4361–4368. 194. BranfordS,RudzkiZ,WalshS,etal.DetectionofBCR-ABLmutations
172. vanLeeuwenRW,vanGelderT,MathijssenRH,etal.Drug-druginter- inpatientswithCMLtreatedwithimatinibisvirtuallyalwaysaccom-
actionswithtyrosine-kinaseinhibitors:aclinicalperspective.LancetOn- paniedbyclinicalresistance,andmutationsintheATPphosphate-
col2014;15:e315–326. bindingloop(P-loop)areassociatedwithapoorprognosis.Blood
173. OsorioS,Escudero-VilaplanaV,Go(cid:4)mez-Centurio(cid:4)nI,etal.Drug-to-drug 2003;102:276–283.
interactionsoftyrosinekinaseinhibitorsinchronicmyeloidleukemiapa- 195. SoveriniS,MartinelliG,RostiG,etal.ABLmutationsinlatechronic
tients.Isitarealproblem?AnnHematol2018;97:2089–2098. phasechronicmyeloidleukemiapatientswithup-frontcytogeneticresis-
174. NoensL,vanLierdeMA,DeBockR,etal.Prevalence,determinants,and tancetoimatinibareassociatedwithagreaterlikelihoodofprogression
outcomesofnonadherencetoimatinibtherapyinpatientswithchronic toblastcrisisandshortersurvival:astudybytheGIMEMAWorking
myeloidleukemia:theADAGIOstudy.Blood2009;113:5401–5411. PartyonChronicMyeloidLeukemia.JClinOncol2005;23:4100–4109.
175. MarinD,BazeosA,MahonFX,etal.Adherenceisthecriticalfactorfor 196. NicoliniFE,CormS,Le^QH,etal.Mutationstatusandclinicaloutcome
achievingmolecularresponsesinpatientswithchronicmyeloidleuke- of89imatinibmesylate-resistantchronicmyelogenousleukemiapa-
miawhoachievecompletecytogeneticresponsesonimatinib.JClin tients:aretrospectiveanalysisfromtheFrenchintergroupofCML
Oncol2010;28:2381–2388. (Fi(phi)-LMCGROUP).Leukemia2006;20:1061–1066.
176. IbrahimAR,EliassonL,ApperleyJF,etal.Pooradherenceisthemain 197. SoveriniS,ColarossiS,GnaniA,etal.ContributionofABLkinasedo-
reasonforlossofCCyRandimatinibfailureforchronicmyeloidleuke- mainmutationstoimatinibresistanceindifferentsubsetsofPhiladel-
miapatientsonlong-termtherapy.Blood2011;117:3733–3736. phia-positivepatients:bytheGIMEMAWorkingPartyonChronic
MyeloidLeukemia.ClinCancerRes2006;12:7374–7379.
177. WuEQ,GuerinA,YuAP,etal.Retrospectivereal-worldcomparisonof
medicalvisits,costs,andadherencebetweennilotinibanddasatinibin 198. KhorashadJS,deLavalladeH,ApperleyJF,etal.Findingofkinasedo-
chronicmyeloidleukemia.CurrMedResOpin2010;26:2861–2869. mainmutationsinpatientswithchronicphasechronicmyeloidleukemia
respondingtoimatinibmayidentifythoseathighriskofdiseasepro-
178. YoodMU,OliveriaSA,CzirakyM,etal.Adherencetotreatmentwith gression.JClinOncol2008;26:4806–4813.
second-linetherapies,dasatinibandnilotinib,inpatientswithchronic
myeloidleukemia.CurrMedResOpin2012;28:213–219. 199. SoveriniS,GnaniA,ColarossiS,etal.Philadelphia-positivepatients
179. Quinta(cid:4)s-CardamaA,CortesJE,KantarjianHM.Practicalmanagement whoalreadyharborimatinib-resistantBCR-ABLkinasedomainmuta-
tionshaveahigherlikelihoodofdevelopingadditionalmutationsasso-
oftoxicitiesassociatedwithtyrosinekinaseinhibitorsinchronicmyeloid
leukemia.ClinLymphomaMyeloma2008;8(Suppl3):S82–88. ciatedwithresistancetosecond-orthird-linetyrosinekinaseinhibitors.
Blood2009;114:2168–2171.
180. CornelisonM,JabbourEJ,WelchMA.Managingsideeffectsoftyrosine
200. HughesT,SaglioG,BranfordS,etal.ImpactofbaselineBCR-ABLmu-
kinaseinhibitortherapytooptimizeadherenceinpatientswithchronic
tationsonresponsetonilotinibinpatientswithchronicmyeloidleuke-
myeloidleukemia:theroleofthemidlevelpractitioner.JSupportOncol
2012;10:14–24.
miainchronicphase.JClinOncol2009;27:4204–4210.
201. NaqviK,CortesJE,LuthraR,etal.Characteristicsandoutcomeof
181. CortesJE,LiptonJH,MillerCB,etal.Evaluatingtheimpactofaswitch
chronicmyeloidleukemiapatientswithE255K/VBCR-ABLkinasedo-
tonilotinibonimatinib-relatedchroniclow-gradeadverseeventsinpa-
tientswithCML-CP:theENRICHstudy.ClinLymphomaMyelomaLeuk
mainmutations.IntJHematol2018;107:689–695.
2016;16:286–296. 202. NicoliniFE,HayetteS,CormS,etal.Clinicaloutcomeof27imatinib
182. KimDW,SausseleS,WilliamsLA,etal.Outcomesofswitchingtodasa- mesylate-resistantchronicmyelogenousleukemiapatientsharboringa
tinibafterimatinib-relatedlow-gradeadverseeventsinpatientswith
T315IBCR-ABLmutation.Haematologica2007;92:1238–1241.
chronicmyeloidleukemiainchronicphase:theDASPERSEstudy.Ann 203. JabbourE,KantarjianHM,JonesD,etal.Characteristicsandoutcomes
Hematol2018;97:1357–1367. ofpatientswithchronicmyeloidleukemiaandT315Imutationfollowing
183. ThomasJ,WangL,ClarkRE,etal.Activetransportofimatinibintoand
failureofimatinibmesylatetherapy.Blood2008;112:53–55.
outofcells:implicationsfordrugresistance.Blood2004;104:3739–3745. 204. SoveriniS,ColarossiS,GnaniA,etal.ResistancetodasatinibinPhila-
184. MahonFX,HayetteS,LagardeV,etal.Evidencethatresistancetonilo- delphia-positiveleukemiapatientsandthepresenceortheselectionof
tinibmaybeduetoBCR-ABL,Pgp,orSrckinaseoverexpression.Can- mutationsatresidues315and317intheBCR-ABLkinasedomain.
cerRes2008;68:9809–9816. Haematologica2007;92:401–404.
185. HegedusC,Ozvegy-LaczkaC,Apa(cid:4)tiA,etal.Interactionofnilotinib,da- 205. JabbourE,KantarjianHM,JonesD,etal.Characteristicsandoutcome
satinibandbosutinibwithABCB1andABCG2:implicationsforaltered ofchronicmyeloidleukemiapatientswithF317LBCR-ABLkinasedo-
anti-cancereffectsandpharmacologicalproperties.BrJPharmacol mainmutationaftertherapywithtyrosinekinaseinhibitors.Blood2008;
2009;158:1153–1164. 112:4839–4842.
186. PicardS,TitierK,EtienneG,etal.Troughimatinibplasmalevelsareas- 206. Mu€llerMC,CortesJE,KimDW,etal.Dasatinibtreatmentofchronic-
sociatedwithbothcytogeneticandmolecularresponsestostandard- phasechronicmyeloidleukemia:analysisofresponsesaccordingtopre-
doseimatinibinchronicmyeloidleukemia.Blood2007;109:3496–3499. existingBCR-ABLmutations.Blood2009;114:4944–4953.
187. LarsonRA,DrukerBJ,GuilhotF,etal.Imatinibpharmacokineticsandits 207. KhouryHJ,CortesJE,KantarjianHM,etal.Bosutinibisactiveinchronic
correlationwithresponseandsafetyinchronic-phasechronicmyeloid phasechronicmyeloidleukemiaafterimatinibanddasatiniband/orni-
leukemia:asubanalysisoftheIRISstudy.Blood2008;111:4022–4028. lotinibtherapyfailure.Blood2012;119:3403–3412.
188. BouchetS,TitierK,MooreN,etal.Therapeuticdrugmonitoringofima- 208. EideCA,ZabriskieMS,SavageStevensSL,etal.Combiningthealloste-
tinibinchronicmyeloidleukemia:experiencefrom1216patientsata ricinhibitorasciminibwithponatinibsuppressesemergenceofandre-
centralizedlaboratory.FundamClinPharmacol2013;27:690–697. storesefficacyagainsthighlyresistantBCR-ABL1mutants.CancerCell
2019;36:431–443.e5.
189. WhiteDL,RadichJ,SoveriniS,etal.Chronicphasechronicmyeloidleu-
kemiapatientswithlowOCT-1activityrandomizedtohigh-doseimatinib 209. KhorashadJS,KelleyTW,SzankasiP,etal.BCR-ABL1compoundmuta-
achievebetterresponsesandhavelowerfailureratesthanthoseran- tionsintyrosinekinaseinhibitor-resistantCML:frequencyandclonalre-
domizedtostandard-doseimatinib.Haematologica2012;97:907–914. lationships.Blood2013;121:489–498.
190. GiannoudisA,DaviesA,LucasCM,etal.Effectivedasatinibuptake 210. ZabriskieMS,EideCA,TantravahiSK,etal.BCR-ABL1compoundmu-
mayoccurwithouthumanorganiccationtransporter1(hOCT1):impli- tationscombiningkeykinasedomainpositionsconferclinicalresistance
cationsforthetreatmentofimatinib-resistantchronicmyeloidleukemia. toponatinibinPhchromosome-positiveleukemia.CancerCell2014;26:
Blood2008;112:3348–3354. 428–442.
191. HiwaseDK,SaundersV,HewettD,etal.Dasatinibcellularuptakeand 211. DeiningerMW,HodgsonJG,ShahNP,etal.Compoundmutationsin
effluxinchronicmyeloidleukemiacells:therapeuticimplications.Clin BCR-ABL1arenotmajordriversofprimaryorsecondaryresistanceto
CancerRes2008;14:3881–3888. ponatinibinCP-CMLpatients.Blood2016;127:703–712.
192. DaviesA,JordanidesNE,GiannoudisA,etal.Nilotinibconcentrationin 212. LaudadioJ,DeiningerMW,MauroMJ,etal.Anintron-derivedinser-
celllinesandprimaryCD34(1)chronicmyeloidleukemiacellsisnot tion/truncationmutationintheBCR-ABLkinasedomaininchronicmye-
mediatedbyactiveuptakeoreffluxbymajordrugtransporters.Leuke- loidleukemiapatientsundergoingkinaseinhibitortherapy.JMolDiagn
mia2009;23:1999–2006. 2008;10:177–180.
66 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024

ChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®
213. BermanE,JhanwarS,HedvatC,etal.Resistancetoimatinibinpatients 234. GugliottaG,CastagnettiF,BrecciaM,etal.Treatment-freeremis-
withchronicmyelogenousleukemiaandthesplicevariantBCR- sioninchronicmyeloidleukemiapatientstreatedfront-linewith
ABL1(35INS).LeukRes2016;49:108–112. nilotinib:10-yearfollowupoftheGIMEMACML0307study.
214. SoveriniS,BranfordS,NicoliniFE,etal.ImplicationsofBCR-ABL1 Haematologica2022;107:2356–2364.
kinasedomain-mediatedresistanceinchronicmyeloidleukemia. 235. LegrosL,NicoliniFE,EtienneG,etal.Secondtyrosinekinaseinhibitor
LeukRes2014;38:10–20. discontinuationattemptinpatientswithchronicmyeloidleukemia.
215. BranfordS,RudzkiZ,ParkinsonI,etal.Real-timequantitativePCRanal- Cancer2017;123:4403–4410.
ysiscanbeusedasaprimaryscreentoidentifypatientswithCML 236. RichterJ,Lu€bkingA,So€derlundS,etal.Molecularstatus36monthsafter
treatedwithimatinibwhohaveBCR-ABLkinasedomainmutations. TKIdiscontinuationinCMLishighlypredictiveforsubsequentlossof
Blood2004;104:2926–2932. MMR-finalreportfromAFTER-SKI.Leukemia2021;35:2416–2418.
216. WangL,KnightK,LucasC,etal.TheroleofserialBCR-ABLtranscript 237. ShanmuganathanN,PaganiIS,RossDM,etal.EarlyBCR-ABL1kinetics
monitoringinpredictingtheemergenceofBCR-ABLkinasemutations arepredictiveofsubsequentachievementoftreatment-freeremissionin
inimatinib-treatedpatientswithchronicmyeloidleukemia.Haematolog- chronicmyeloidleukemia.Blood2021;137:1196–1207.
ica2006;91:235–239.
238. CortesJE,ApperleyJF,DeAngeloDJ,etal.Managementofadverse
217. KantarjianHM,ShanJ,JonesD,etal.Significanceofincreasinglevels
eventsassociatedwithbosutinibtreatmentofchronic-phasechronic
ofminimalresidualdiseaseinpatientswithPhiladelphiachromosome-
myeloidleukemia:expertpanelreview.JHematolOncol2018;11:143.
positivechronicmyelogenousleukemiaincompletecytogeneticre-
sponse.JClinOncol2009;27:3659–3663. 239. KotaV,Bru€mmendorfTH,Gambacorti-PasseriniC,etal.Efficacyand
safetyfollowingbosutinibdosereductioninpatientswithPhiladelphia
218. MarinD,KhorashadJS,ForoniL,etal.DoesariseintheBCR-ABL1 chromosome–positiveleukemias.LeukRes2021;111:106690.
transcriptlevelidentifychronicphaseCMLpatientsrespondingtoimati-
nibwhohaveahighriskofcytogeneticrelapse?BrJHaematol2009; 240. NaqviK,JabbourE,SkinnerJ,etal.Long-termfollow-upoflowerdose
145:373–375. dasatinib(50mgdaily)asfrontlinetherapyinnewlydiagnosedchronic-
phasechronicmyeloidleukemia.Cancer2020;126:67–75.
219. PressRD,WillisSG,LaudadioJ,etal.DeterminingtheriseinBCR-ABL
RNAthatoptimallypredictsakinasedomainmutationinpatientswith 241. JabbourE,SasakiK,HaddadFG,etal.Low-dosedasatinib50mg/day
chronicmyeloidleukemiaonimatinib.Blood2009;114:2598–2605. versusstandard-dosedasatinib100mg/dayasfrontlinetherapyin
220. MahonFX,Re(cid:4)aD,GuilhotJ,etal.Discontinuationofimatinibinpa- chronicmyeloidleukemiainchronicphase:apropensityscoreanalysis.
tientswithchronicmyeloidleukaemiawhohavemaintainedcomplete
AmJHematol2022;97:1413–1418.
molecularremissionforatleast2years:theprospective,multicentre 242. ItamuraH,KubotaY,ShindoT,etal.Elderlypatientswithchronicmye-
StopImatinib(STIM)trial.LancetOncol2010;11:1029–1035. loidleukemiabenefitfromadasatinibdoseaslowas20mg.ClinLym-
221. EtienneG,GuilhotJ,Re(cid:4)aD,etal.Long-termfollow-upoftheFrench phomaMyelomaLeuk2017;17:370–374.
StopImatinib(STIM1)studyinpatientswithchronicmyeloidleukemia. 243. MuraiK,UreshinoH,KumagaiT,etal.Low-dosedasatinibinolderpa-
JClinOncol2017;35:298–305. tientswithchronicmyeloidleukaemiainchronicphase(DAVLEC):asin-
222. ThielenN,vanderHoltB,CornelissenJJ,etal.Imatinibdiscontinuation
gle-arm,multicentre,phase2trial.LancetHaematol2021;8:e902–911.
inchronicphasemyeloidleukaemiapatientsinsustainedcompletemo- 244. VisaniG,BrecciaM,GozziniA,etal.Dasatinib,evenatlowdoses,isan
lecularresponse:arandomisedtrialoftheDutch-BelgianCooperative effectivesecond-linetherapyforchronicmyeloidleukemiapatientsre-
TrialforHaemato-Oncology(HOVON).EurJCancer2013;49:3242–3246. sistantorintoleranttoimatinib.Resultsfromareallife-basedItalianmul-
223. RousselotP,CharbonnierA,Cony-MakhoulP,etal.Lossofmajormo- ticenterretrospectivestudyon114patients.AmJHematol2010;85:
lecularresponseasatriggerforrestartingtyrosinekinaseinhibitorther- 960–963.
apyinpatientswithchronic-phasechronicmyelogenousleukemiawho 245. LaRose(cid:4)eP,MartiatP,LeitnerA,etal.Improvedtolerabilitybyamodi-
havestoppedimatinibafterdurableundetectabledisease.JClinOncol fiedintermittenttreatmentscheduleofdasatinibforpatientswith
2014;32:424–430.
chronicmyeloidleukemiaresistantorintoleranttoimatinib.AnnHema-
224. MoriS,VaggeE,leCoutreP,etal.AgeanddPCRcanpredictrelapse tol2013;92:1345–1350.
inCMLpatientswhodiscontinuedimatinib:theISAVstudy.AmJ 246. Hjorth-HansenH,StenkeL,So€derlundS,etal.Dasatinibinducesfast
Hematol2015;90:910–914.
anddeepresponsesinnewlydiagnosedchronicmyeloidleukaemiapa-
225. LeeSE,ChoiSY,SongHY,etal.Imatinibwithdrawalsyndromeandlon- tientsinchronicphase:clinicalresultsfromarandomisedphase-2study
gerdurationofimatinibhaveacloseassociationwithalowermolecular (NordCML006).EurJHaematol2015;94:243–250.
r 2e 0l 1ap 6;s 1e 0a 1f :t 7e 1r 7t –re 7a 2t 3m .entdiscontinuation:theKIDstudy.Haematologica 247. IriyamaN,OhashiK,HashinoS,etal.Theefficacyofreduced-doseda-
satinibasasubsequenttherapyinpatientswithchronicmyeloidleuke-
226. RossDM,PaganiIS,ShanmuganathanN,etal.Long-termtreatment- miainthechronicphase:theLD-CMLstudyoftheKANTOCMLstudy
freeremissionofchronicmyeloidleukemiawithfallinglevelsofresidual group.InternMed2018;57:17–23.
leukemiccells.Leukemia2018;32:2572–2579.
248. OhnishiK,NakasekoC,TakeuchiJ,etal.Long-termoutcomefollowing
227. Re(cid:4)aD,NicoliniFE,TulliezM,etal.Discontinuationofdasatiniborniloti- imatinibtherapyforchronicmyelogenousleukemia,withassessmentof
nibinchronicmyeloidleukemia:interimanalysisoftheSTOP2G-TKI
dosageandbloodlevels:theJALSGCML202study.CancerSci2012;
study.Blood2017;129:846–854.
103:1071–1078.
228. OkadaM,ImagawaJ,TanakaH,etal.Final3-yearresultsofthedasati- 249. TokuhiraM,KimuraY,SugimotoK,etal.Efficacyandsafetyofnilotinib
nibdiscontinuationtrialinpatientswithchronicmyeloidleukemiawho
therapyinpatientswithnewlydiagnosedchronicmyeloidleukemiain
receiveddasatinibasasecond-linetreatment.ClinLymphomaMyeloma
Leuk2018;18:353–360.e1. thechronicphase.MedOncol2018;35:38.
250. HiwaseD,TanP,D’RozarioJ,etal.Efficacyandsafetyofnilotinib
229. SausseleS,RichterJ,GuilhotJ,etal.Discontinuationoftyrosinekinase
300mgtwicedailyinpatientswithchronicmyeloidleukemiain
inhibitortherapyinchronicmyeloidleukaemia(EURO-SKI):aprespeci-
fiedinterimanalysisofaprospective,multicentre,non-randomised,trial. chronicphasewhoareintoleranttopriortyrosinekinaseinhibitors:
LancetOncol2018;19:747–757. resultsfromthePhaseIIIbENESTswiftstudy.LeukRes2018;67:
230. ShahNP,Garc(cid:4)ıa-Gutie(cid:4)rrezV,Jime(cid:4)nez-VelascoA,etal.Dasatinibdis-
109–115.
continuationinpatientswithchronic-phasechronicmyeloidleukemia 251. IurloA,CattaneoD,MalatoA,etal.Low-doseponatinibisagoodop-
andstabledeepmolecularresponse:theDASFREEstudy.LeukLym- tioninchronicmyeloidleukemiapatientsintoleranttopreviousTKIs.
phoma2020;61:650–659. AmJHematol2020;95:E260–263.
231. KimuraS,ImagawaJ,MuraiK,etal.Treatment-freeremissionafterfirst- 252. RussoD,MalagolaM,SkertC,etal.Managingchronicmyeloidleukae-
linedasatinibdiscontinuationinpatientswithchronicmyeloidleukaemia miaintheelderlywithintermittentimatinibtreatment.BloodCancerJ
(first-lineDADItrial):asingle-arm,multicentre,phase2trial.LancetHae- 2015;5:e347.
matol2020;7:e218–225. 253. FaberE,Divoka(cid:4)M,Skoumalova(cid:4)I,etal.Alowerdosageofimatinibis
232. RadichJP,HochhausA,MassziT,etal.Treatment-freeremissionfollowing sufficienttomaintainundetectablediseaseinpatientswithchronicmye-
frontlinenilotinibinpatientswithchronicphasechronicmyeloidleukemia: loidleukemiawithlong-termlow-gradetoxicityofthetreatment.Leuk
5-yearupdateoftheENESTfreedomtrial.Leukemia2021;35:1344–1355. Lymphoma2016;57:370–375.
233. HughesTP,ClementinoNCD,FominykhM,etal.Long-termtreatment- 254. CervantesF,CorreaJG,Pe(cid:4)rezI,etal.Imatinibdosereductionin
freeremissioninpatientswithchronicmyeloidleukemiaaftersecond- patientswithchronicmyeloidleukemiainsustaineddeepmolecular
linenilotinib:ENESTop5-yearupdate.Leukemia2021;35:1631–1642. response.AnnHematol2017;96:81–85.
JNCCN.org | Volume22 Issue1 | February2024 67

NCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024
255. ClarkRE,PolydorosF,ApperleyJF,etal.De-escalationoftyrosine termdiseasecontrolinchronicmyeloidleukemia.LeukLymphoma
kinaseinhibitordoseinpatientswithchronicmyeloidleukaemiawith 2019;60:1796–1802.
stablemajormolecularresponse(DESTINY):aninterimanalysisofa 277. StellaS,Tirro(cid:4)E,MassiminoM,etal.Successfulmanagementofapreg-
non-randomised,phase2trial.LancetHaematol2017;4:e310–316.
nantpatientwithchronicmyeloidleukemiareceivingstandarddoseim-
256. ClarkRE,PolydorosF,ApperleyJF,etal.De-escalationoftyrosine atinib.InVivo2019;33:1593–1598.
kinaseinhibitortherapybeforecompletetreatmentdiscontinuation 278. AliR,Ozkalemkas¸F,OzkocamanV,etal.Successfulpregnancyandde-
inpatientswithchronicmyeloidleukaemia(DESTINY):anon-randomised, liveryinapatientwithchronicmyelogenousleukemia(CML),andman-
phase2trial.LancetHaematol2019;6:e375–383.
agementofCMLwithleukapheresisduringpregnancy:acasereport
257. CayssialsE,Torregrosa-DiazJ,Gallego-HernanzP,etal.Low-dosetyro- andreviewoftheliterature.JpnJClinOncol2004;34:215–217.
sinekinaseinhibitorsbeforetreatmentdiscontinuationdonotimpair 279. KohLP,KanagalingamD.Pregnanciesinpatientswithchronicmyeloid
treatment-freeremissioninchronicmyeloidleukemiapatients:resultsof leukemiaintheeraofimatinib.IntJHematol2006;84:459–462.
aretrospectivestudy.Cancer2020;126:3438–3447.
280. PalaniR,MilojkovicD,ApperleyJF.Managingpregnancyinchronicmy-
258. ClaudianiS,ApperleyJF,SzydloR,etal.TKIdosereductioncaneffec- eloidleukaemia.AnnHematol2015;94(Suppl2):S167–176.
tivelymaintainmajormolecularremissioninpatientswithchronicmye-
loidleukaemia.BrJHaematol2021;193:346–355. 281. StaleyEM,SimmonsSC,FeldmanAZ,etal.Managementofchronic
myeloidleukemiainthesettingofpregnancy:whenisleukocytapheresis
259. MalagolaM,IurloA,AbruzzeseE,etal.Molecularresponseandquality appropriate?Acasereportandreviewoftheliterature.Transfusion
oflifeinchronicmyeloidleukemiapatientstreatedwithintermittent 2018;58:456–460.
TKIs:firstinterimanalysisofOPTkIMAstudy.CancerMed2021;10:
1726–1737. 282. OJa bm se tes tA GH y, nB ecra on lc Sa uz ri vo 2L 0R 0, 8P ;r 6ic 3e :4T 9. –A 57sp .irinandreproductiveoutcomes.
260. HoffmannVS,BaccaraniM,HasfordJ,etal.TheEUTOSpopulation-
283. DeruelleP,CoulonC.Theuseoflow-molecular-weightheparinsinpreg-
b tiea nse tsd inre 2g 0ist Ery u: roin pc eid anen Cc oe ua nn td riec sl .in Lic ea ul kc eh ma ir aac 2t 0e 1ri 5st ;2ic 9s :1o 3f 32 69 –0 14 3C 43M .Lpa- nancy–howsafearethey?CurrOpinObstetGynecol2007;19:573–577.
284. BaykalC,ZenginN,Cos¸kunF,etal.Useofhydroxyureaandalpha-
261. RamasamyK,HaydenJ,LimZ,etal.Successfulpregnanciesinvolving
interferoninchronicmyeloidleukemiaduringpregnancy:acase
m 20e 0n 7;w 1i 3th 7:c 3h 7r 4o –n 3i 7c 5m .yeloidleukaemiaonimatinibtherapy.BrJHaematol report.EurJGynaecolOncol2000;21:89–90.
285. Thauvin-RobinetC,MaingueneauC,RobertE,etal.Exposuretohydroxy-
262. BrecciaM,CannellaL,MontefuscoE,etal.Malepatientswithchronic ureaduringpregnancy:acaseseries.Leukemia2001;15:1309–1311.
myeloidleukemiatreatedwithimatinibinvolvedinhealthypregnancies:
reportoffivecases.LeukRes2008;32:519–520. 286. FadilahSA,Ahmad-ZailaniH,Soon-KengC,etal.Successfultreatment
ofchronicmyeloidleukemiaduringpregnancywithhydroxyurea.Leuke-
263. OweiniH,OtrockZK,MahfouzRA,etal.Successfulpregnancyinvolving mia2002;16:1202–1203.
amanwithchronicmyeloidleukemiaondasatinib.ArchGynecol
Obstet2011;283:133–134. 287. BalsatM,EtienneM,ElhamriM,etal.Successfulpregnanciesinpa-
tientswithBCR-ABL-positiveleukemiastreatedwithinterferon-alpha
264. GhalautVS,PrakashG,BansalP,etal.Effectofimatinibonmale
therapyduringthetyrosinekinaseinhibitorsera.EurJHaematol2018;
r lie mp ir no ad ryuc rt ei pve orh to .Jrm Oo nn ce os li Pn hB aC rmR- PA rB aL ctp 2o 0s 1it 4iv ;2e 0C :2M 4L 3–p 2a 4t 8ie .nts:apre- 101:774–780.
288. BeauverdY,RadiaD,CargoC,etal.Pegylatedinterferonalpha-2afor
265. AlizadehH,JaafarH,RajnicsP,etal.Outcomeofpregnancyinchronic
essentialthrombocythemiaduringpregnancy:outcomeandsafety.A
m rey pe ol ro tid frole muk aae sim ngia lep ca eti ne tn rets .t Lr ee ua kte Rd ew si 2th 01t 5yr ;3o 9si :n 4e 7–k 5in 1a .seinhibitors:short caseseries.Haematologica2016;101:e182–184.
289. SchrickelL,HeidelFH,SadjadianP,etal.Interferonalphaforessential
266. PyeSM,CortesJE,AultP,etal.Theeffectsofimatinibonpregnancy
outcome.Blood2008;111:5505–5508. t Jh Cro am ncb eo rc Ryt eh se Cm lii na Odu nr cin og l23 04 2h 1i ;g 1h 4- 7r :i 1sk 48p 1re –1g 4n 9a 1n .cies:outcomeandsafety.
267. pC ro er gte ns anJE cy,A ob utr cu ozz me ese s.E A, mCh Je Hly esh me av ta olE 2, 0e 1t 5a ;l 9. 0T :h 1e 11im 1–p 1a 1c 1t 5o .fdasatinibon 290. BurchertA,Mu€llerMC,KostrewaP,etal.Sustainedmolecularresponse
withinterferonalfamaintenanceafterinductiontherapywithimatinib
268. BarkoulasT,HallPD.Experiencewithdasatinibandnilotinibusein plusinterferonalfainpatientswithchronicmyeloidleukemia.JClinOn-
pregnancy.JOncolPharmPract2018;24:121–128. col2010;28:1429–1435.
269. SalemW,LiK,KrappC,etal.Imatinibtreatmentshavelong-termim- 291. AbruzzeseE,TurkinaAG,ApperleyJF,etal.Pregnancymanagementincml
pactonplacentationandembryosurvival.SciRep2019;9:2535. patients:totreatornottotreat?Reportof224outcomesoftheEuropean
270. MadabhaviI,SarkarM,ModiM,etal.Pregnancyoutcomesinchronic LeukemiaNet(ELN)database.Blood2019;134(Suppl1):Abstract632.
myeloidleukemia:asinglecenterexperience.JGlobOncol2019;5:1–11.
292. RussellMA,CarpenterMW,AkhtarM,etal.Imatinibmesylateandme-
271. CortesJE,Gambacorti-PasseriniC,DeiningerMW,etal.Pregnancy taboliteconcentrationsinmaternalblood,umbilicalcordblood,pla-
outcomesinpatientstreatedwithbosutinib.IntJHematolOncol centaandbreastmilk.JPerinatol2007;27:241–243.
2020;9:IJH26. 293. AliR,OzkalemkasF,KimyaY,etal.Imatinibuseduringpregnancyand
272. AssiR,KantarjianHM,KeatingM,etal.Managementofchronicmye- breastfeeding:acasereportandreviewoftheliterature.ArchGynecol
loidleukemiaduringpregnancyamongpatientstreatedwithatyrosine Obstet2009;280:169–175.
kinaseinhibitor:asingle-centerexperience.LeukLymphoma2021;62: 294. USNationalInstitutesofHealth.Drugsandlactationdatabase
909–917.
(LactMed).AccessedNovember1,2023.Availableat:https://
273. AultP,KantarjianHM,O’BrienS,etal.Pregnancyamongpatientswith www.ncbi.nlm.nih.gov/books/NBK501922/
chronicmyeloidleukemiatreatedwithimatinib.JClinOncol2006;24: 295. ChelyshevaE,AleshinS,PolushkinaE,etal.Breastfeedinginpatients
1204–1208.
withchronicmyeloidleukaemia:caseserieswithmeasurementsofdrug
274. KuwabaraA,BabbA,IbrahimA,etal.Pooroutcomeafterreintroduc- concentrationsinmaternalmilkandliteraturereview.MediterrJHema-
tionofimatinibinpatientswithchronicmyeloidleukemiawhointerrupt tolInfectDis2018;10:e2018027.
therapyonaccountofpregnancywithouthavingachievedanoptimal 296. AbruzzeseE,TrawinskaMM,PerrottiAP,etal.Tyrosinekinaseinhibitors
response.Blood2010;116:1014–1016.
andpregnancy.MediterrJHematolInfectDis2014;6:e2014028.
275. BermanE.Familyplanningandpregnancyinpatientswithchronicmye- 297. HochhausA,SaglioG,HughesTP,etal.Long-termbenefitsandrisks
loidleukemia.CurrHematolMaligRep2023;18:33–39.
offrontlinenilotinibvsimatinibforchronicmyeloidleukemiainchronic
276. LasicaM,WillcoxA,BurburyK,etal.Theeffectoftyrosinekinaseinhibi- phase:5-yearupdateoftherandomizedENESTndtrial.Leukemia2016;
torinterruptionandinterferonuseonpregnancyoutcomesandlong- 30:1044–1054.
68 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024

ChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®
IndividualDisclosuresfortheNCCNChronicMyeloidLeukemiaPanel
PromotionalAdvisory
ClinicalResearchSupport/DataSafety ScientificAdvisoryBoards,Consultant,or Boards,Consultant,or
PanelMember MonitoringBoard ExpertWitness SpeakersBureau Specialization
JessicaK.Altman,MD AbbVie,Inc.;ALXOncology;AmgenInc.;Aprea;Aptos; AstellasPharmaUS,Inc.;BlueBirdBio;Curio; GlycoMimetics,Inc. Hematology/Hematologyoncology
AstellasPharmaUS,Inc.;BioSight;BristolMyersSquibb; Daiichi-SankyoCo.;GileadSciences,Inc.;
Cellectis;FujifilmCorporation;GileadSciences,Inc.; KuraOncology,Inc.;Kymera;Stemline;Syros
GlycoMimetics,Inc.;ImmunoGen,Inc.;Kartos;Kura Pharmaceuticals
Oncology,Inc.;MEIPharmaInc.;Rafael;Telios
MariaAmaya,MD,PhD None None None Hematology/Hematologyoncology
KebedeH.Begna,MD None NovartisPharmaceuticalsCorporation None Hematology/Hematologyoncology
EllinBerman,MD NovartisPharmaceuticalsCorporation None None Hematology/Hematologyoncology;
Medicaloncology;Internal
medicine
RaviBhatia,MD None None None Hematology/Hematologyoncology
OnyeeChan,MD CullinanOncology;JazzPharmaceuticalsInc.;Magenta None BristolMyersSquibb; Hematology/Hematologyoncology
Therapeutics NeuroVascularResearch&
Design;TFHealthCo.
JoanClements None KaiserPermanente;NovartisPharmaceuticals NovartisPharmaceuticals Patientadvocacy
Corporation;PfizerInc. Corporation
RobertH.CollinsJr,MD None Ro5Inc. None Hematology/Hematologyoncology
PeterT.Curtin,MD CRISPRTherapeutics None None Medicaloncology;Hematology/
Hematologyoncology;
Hematopoieticcelltransplantation
DanielJ.DeAngelo,MD,PhD AbbVie,Inc.;BlueprintMedicines;Daiichi-SankyoCo.; None None Hematology/Hematologyoncology;
GlycoMimetics,Inc.;JazzPharmaceuticalsInc.;Kite Medicaloncology
Pharma;MtSinaiMPNConsortium;Novartis
PharmaceuticalsCorporation
MichaelDrazer,MD None Argenx None Hematology/Hematologyoncology
LoriManess,MD None None None Hematology/Hematologyoncology
LelandMetheny,MD Adienne;PfizerInc. Gamida;IncyteCorporation;PfizerInc./ None Hematology/Hematologyoncology;
HospiraInc. Internalmedicine
SanjayMohan,MD,MSCI Ichnos;IncyteCorporation;Kartos;Karyopharm None None Hematology/Hematologyoncology
Therapeutics;TaihoPharmaceuticalsCo.,Ltd.
JosephO.Moore,MD Pharmacyclics Pharmacyclics JanssenPharmaceutica Medicaloncology
Products,LP
VivianOehler,MD Actuate/CouranteOncology;Ascentage;Astex NovartisPharmaceuticalsCorporation None Hematology/Hematologyoncology
Pharmaceuticals;BristolMyersSquibb;PfizerInc.
KeithPratz,MD AbbVie,Inc.;AstellasPharmaUS,Inc.;Takeda AbbVie,Inc.;AstellasPharmaUS,Inc.; None Medicaloncology
PharmaceuticalsNorthAmerica,Inc. AstraZenecaPharmaceuticalsLP;Bristol
MyersSquibb;RocheLaboratories,Inc.;
Servier
IskraPusic,MD,MSCI GSK;IncyteCorporation;Kadmon;SYNDAX IncyteCorporation;Syndax None Medicaloncology
MichalG.Rose,MD None None None Medicaloncology
NeilP.Shah,MD,PhD AerovateTherapeutics;BristolMyersSquibb;Taiho AerovateTherapeutics None Hematology/Hematologyoncology
PharmaceuticalsCo.,Ltd.
WilliamShomali,MD BlueprintMedicines;IncyteCorporation IncyteCorporation None Hematology/Hematologyoncology
B.DouglasSmith,MD None BristolMyersSquibb;Novartis None Medicaloncology;Internal
PharmaceuticalsCorporation;PfizerInc.; medicine
Servier
MichaelStyler,MD JanssenPharmaceuticaProducts,LP None None Hematology/Hematologyoncology;
Medicaloncology
MosheTalpaz,MD None BristolMyersSquibb;Novartis None Medicaloncology
PharmaceuticalsCorporation;Sumitomo
TiffanyN.Tanaka,MD None None CTIBioPharmaCorp.; Hematology/Hematologyoncology
GileadSciences,Inc.
SrinivasTantravahi,MBBS KaryopharmTherapeutics AbbVie,Inc.;CTIBioPharmaCorp.;Guidant None Hematology/Hematologyoncology
Corporation;KaryopharmTherapeutics;
MorphoSysAG;NovartisPharmaceuticals
Corporation
JamesThompson,MD,MS BristolMyersSquibb;NovartisPharmaceuticals None None Hematology/Hematologyoncology
Corporation
StevenTsai,MD None None None Hematology/Hematologyoncology;
Hematopoieticcelltransplantation
JenniferVaughn,MD,MSPH None None CogentPharmaceuticals; Hematology/Hematologyoncology
Ionis
JeannaWelborn,MD None None None Medicaloncology
DavidT.Yang,MD None None None Pathology
TheNCCNGuidelinesStaffhavenoconflictstodisclose.
JNCCN.org | Volume22 Issue1 | February2024 69

